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ABSTRACT OF THE DISSERTATION 
THE INFLUENCE OF NEUROCOGNITIVE IMPAIRMENT, ALCOHOL AND 
OTHER DRUG (AOD) USE, AND PSYCHOSOCIAL FACTORS ON 
ANTIRETROVIRAL TREATMENT ADHERENCE, SERVICE UTILIZATION AND 
VIRAL LOAD AMONG HIV-SEROPOSITIVE ADULTS  
by  
Jennifer Attonito 
Florida International University, 2013  
Miami, Florida  
Jessy G. Dévieux, Major Professor 
Among people living with HIV (PLWH), adherence to antiretroviral therapy 
(ART) can be affected by problems of neurocognitive (NC) impairment, stress, alcohol 
and other drug (AOD) abuse, and other barriers. The aims of this research were to: (1) 
examine factors associated with NC impairment, (2) explore relationships between 
psychosocial variables with ART adherence and viral load (VL), and (3) evaluate the 
efficacy of an evidence-based intervention in improving ART adherence, increasing 
service utilization, and decreasing VL.  
The first study (n=370) was cross sectional and used structural equation modeling 
to test whether AOD use, years living with HIV, and time from HIV diagnosis to seeking 
care were associated with poorer NC functioning. The second study (n=246) used similar 
methods to test the hypothesis that stress, barriers to adherence, NC impairment, poor 
social support, and AOD use were related to lower VL mediated by ART adherence. The 
third study (n=243) evaluated an evidence-based, eight-session program to improve ART 
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adherence, reduce VL, and increase service utilization in a randomized controlled trial. 
Study participants were PLWH living in South Florida, 18 to 60 years old, with a history 
of alcohol abuse enrolled from January 2009 through November 2012.  
Secondary analysis of available data showed: (1) scores on interference with 
executive functioning increased by 0.32 for each day of marijuana use and 1.18 for each 
year living with HIV, but no association was found between alcohol use and NC 
functioning; (2) each barrier to adherence was associated with a 10% decrease in 
adherence to ART and a 0.42 unit increase in VL (log10) and the relationship between 
barriers and VL was partially mediated by ART adherence; (3) participants in the 
evidence-based program were more likely than the comparison group to report an 
undetectable VL (OR=2.25, p<0.01) at 6 months, but not 3 months, post-intervention.  
Psychosocial factors affect VL, but ART adherence is essential in achieving an 
undetectable VL in PLWH. 
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CHAPTER I 
BACKGROUND 
Treatment for Human Immunodeficiency Virus (HIV) 
Although over 600,000 people in the United States have died from complications 
related to acquired immune deficiency syndrome (AIDS) since the beginning of the 
epidemic, AIDS death rates have decreased dramatically since the mid-1990s. This 
decline is due in great part to the advent of highly active antiretroviral therapy (HAART; 
Centers for Disease Control and Prevention Division of HIV/AIDS, 2012a, 2012b). 
Chemotherapy for human immunodeficiency virus (HIV) has evolved over the years 
from no treatment to treatment with a single drug (AZT or Zidovudine) to dual-drug 
therapy and, since 1996, to HAART (also referred to as ART). ART is defined as 
treatment with at least three active anti-retroviral medications—typically two nucleoside 
or nucleotide reverse transcriptase inhibitors (NRTI’s) plus a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) or another NRTI—and is 
often called the drug “cocktail” or triple-therapy (Thompson, Aberg, & Hoy, 2012). 
Because each class of antiretroviral medications intercepts viral replication and 
proliferation at different stages in the HIV life cycle, a combination of antiretrovirals is 
considered to be most effective for achieving undetectable blood levels of the virus and 
preventing the emergence of resistance.   
HIV Treatment Adherence 
HAART has essentially transformed HIV from a fatal to a chronic illness. Thus, 
the goal of HIV care has shifted toward achieving long-term optimal health outcomes 
through consistent adherence to ART. Proper ART adherence can  stop viral replication, 
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rendering virus levels undetectable in both blood and sexual fluids and reducing risk of 
HIV transmission (Cohen & Chen, 2011; Volkow & Montaner, 2010).  Optimal  
adherence to ART—defined as following prescribed treatment at least 80% of the time 
(Parienti et al., 2008)—directly improves health outcomes and is critical for successful 
treatment (Bangsberg et al., 2000; Carpenter et al., 1997; Deeks, Smith, Holodniy, & 
Kahn, 1997; Descamps & Flandre, 2000; Katzenstein, 1997; Paterson, Swindells, Mohr, 
Brester, & Vergis, 2000).  
Conversely, treatment interruption and inconsistent ART adherence is known to 
result in poorer health outcomes and the emergence of treatment resistant strains of HIV, 
reducing treatment options for an infected individual over time (Parienti et al., 2008; 
Bangsberg et al., 2001). Additionally, these resistant strains may be transmitted to others 
through infected body fluids, resulting in treatment failure and reduced treatment options 
on a community level. Even in a time of heightened awareness of HIV in the U.S., about 
50,000 people continue to be infected annually (Centers for Disease Control and 
Prevention Division of HIV/AIDS, 2012). Because of the convincing body of knowledge 
suggesting that consistent ART adherence can not only improve health outcomes for 
individuals but also reduce HIV transmission at population levels, the Centers for Disease 
Control and Prevention (CDC), National Institutes for Health (NIH), and Health 
Resources and Services Administration (HRSA) have placed increasing priority on 
improving treatment adherence and access to care for people living with HIV (PLWH; 
White House Office of National AIDS Policy, 2010).  
Adherence to ART is possibly the most important determinant of survival among 
PLWH (Hogg et al. 2002) with earlier studies suggesting that as much as 95% adherence 
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was  necessary to achieve positive clinical outcomes with regimens used in the 1990s and 
early 2000s (Bangsberg, Moss, & Deeks, 2004; Lucas, 2005; Paterson et al., 2000). Even 
with the newest regimens, uninterrupted adherence of >80% is typically considered 
essential to guarantee optimal virologic response (Parienti 2008). Furthermore, 
inadequate treatment adherence is associated with increased mortality, drug resistance 
and limited future treatment options for the patient, and increased risk of HIV 
transmission to others (Bangsberg et al., 2001).  
More recently, ART has been shown to be an effective means of HIV prevention. 
Results from the nine-country HIV Prevention Trials Network (HPTN 052) revealed that 
HIV-seropositive partners were significantly less likely to transmit the virus sexually to 
uninfected partners if ART was initiated when CD4 counts were higher (350-499) than 
levels considered absolute indications for ART initiation for patient’s health (CD4 
count<350), indicating potential effectiveness of use of treatment as prevention of sexual 
HIV transmission  (Cohen et al. 2011). Other research has reported similar outcomes in 
the use of treatment-as-prevention for  HIV transmission related to injection drug use 
(Choopanya et al., 2013; Wood, Kerr, & Marshall, 2009). While ART adherence is 
strongly associated with  viral suppression  and reduction of  HIV transmission to others,   
this relationship may be related  to the classes of antiretrovirals  used (Bangsberg et al., 
2004; Katzenstein, 1997) and strain resistance to antiretrovirals used (Liao et al., 2013). 
The reduction of VL has been shown to result in lower rates of new infection on a 
community level (Das et al. 2010). However adequate viral suppression is achieved only 
through treatment adherence by each individual. While efforts to simplify treatment 
particularly to once-a-day one-pill ART, have been successful, ART regimens can still be 
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complicated, requiring patients to take multiple doses daily of each medication in the 
combination (Abgrall & The Antiretroviral Therapy Cohort Collaboration (ART-CC), 
2012). Each medication may also carry specific dose-timing and storage requirements. 
Different medications may need to be taken with food, without food, with water, or in an 
order relative to other drugs in the combination (Catz, Kelly, Bogart, Benotsch, & 
Mcauliffe, 2000). 
Achieving the nearly perfect adherence recommended to suppress viral 
replication, experience optimal health outcomes, and prevent HIV transmission can be 
challenging.   U.S. studies have reported that as few as 18% to 73% of participants were  
non-adherent to antiretroviral therapy (Catz et al., 2000; Paterson et al., 2000; Tesoriero 
et al., 2003). These percentages may be even lower for PLWHs dealing with 
neurocognitive impairment, substance abuse problems, and added environmental and 
psychosocial constraints. Additional predictors of poor ART adherence include poor 
social support (Safren et al., 2001), mental health problems (Bottonari et al., 2012; Nel & 
Kagee, 2011; Sherr, Clucas, Harding, Sibley, & Catalan, 2011), and alcohol abuse (Baum 
et al., 2010; Bryant, 2006; Samet, Phillips, Horton, Traphagen, & Freedberg, 2004), 
which will be discussed in greater detail below. 
In addition to helping individual patients adhere to treatment regimens, the full 
implementation of community-level treatment as prevention (i.e., “seek, test, treat, 
retain”) requires stabilization of many policy and institutional factors, including 
improving access to and utilization of available care (Mayer & Krakower, 2012). 
Increasing access to care and optimizing health outcomes for PLWH is one of the three 
primary goals of the National HIV/AIDS Strategy (White House Office of National AIDS 
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Policy, 2010). It is estimated that as many as 30 percent of people diagnosed with HIV in 
the U.S. are not accessing care (White House Office of National AIDS Policy, 2010). 
Through adequate and consistent care, patients are better able to receive the support 
necessary to achieve complete treatment adherence, sustain optimal health outcomes and, 
ultimately, help to reduce the incidence of HIV. 
HIV-Associated Neurocognitive Impairment 
Over the next 20 years, neuropsychiatric disorders are estimated to exact  a global 
cost of $16.1 trillion with ‘‘dramatic impacts on productivity and quality of life’’ (Bloom 
et al., 2012, p. 5). Mental, neurological, and substance use disorders are associated with 
low rates of care utilization, poor treatment adherence and response, and increases in high 
risk behaviors (Bass et al., 2012).  
With HIV-positive individuals living longer because of increased availability and 
use  of HIV treatments, new neurologic syndromes often associated with HIV status are 
emerging with greater frequency over the life span (Antinori et al., 2007; Durvasula, 
Norman, & Malow, 2009; Norman, Basso, Kumar, & Malow, 2009; Palacio, Alvarez, & 
Munoz-Fernandez, 2012). Thus, it is important to study the effects of neurocognitive 
(NC) impairment on risk behaviors among PLWH. Since the advent of combination 
ART, the incidence of HIV-associated dementia (HAD) has declined from 10-15% 
(Janssen, Nwanyanwu, Selik, & Stehr-Green, 1992; J. McArthur & Grant, 1998)   to 2-
5% (Heaton et al., 2010; Robertson et al., 2007; Sacktor, 2002). However, milder forms 
of HIV-associated neurocognitive disorders (HAND) have been reported in up to 40% of 
this population, especially as HIV-positive individuals are living longer with the disease 
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(Antinori et al., 2007; Durvasula et al., 2009; McArthur, 2004; Sacktor, 2002; Sacktor et 
al., 2007).  
HAND is divided into minor cognitive motor disorder (MCMD) and HAD 
(Antinori et al., 2007). MCMD in turn is subdivided into asymptomatic neurocognitive 
impairment (ANI) and mild neurocognitive disorder (MND). MND is accompanied by 
mild interference in daily functioning, whereas ANI is not (Foley et al., 2010; Gandhi et 
al., 2011). ANI and MND are both identified by performance scores at least one standard 
deviation (SD) below the mean of normative scores in at least two cognitive domains: 
attention-information, processing, language, abstraction-executive, complex perceptual 
motor skills, memory, including learning and recall, simple motor skills or sensory 
perceptual abilities. In contrast, HAD is characterized by marked neurocognitive 
dysfunction (≥ 2 standard deviations below the mean normative scores) in at least two 
cognitive domains. This level of cognitive impairment produces marked interference with 
activities of daily living (Antinori et al., 2007; Foley et al., 2010; Gandhi et al., 2011; 
Gisslén, Price, & Nilsson, 2011; Palacio et al., 2012).  
The types of impairments exhibited by persons with these neurologic syndromes 
can affect functioning at work or in everyday activities (Gandhi et al., 2011). Even 
though HAD has become less frequent, HIV-positive individuals are still at risk for HIV-
associated neurological complications. Two to five percent of HIV-positive individuals 
are estimated to develop HAD  and up to 37% will suffer a less severe ANI or MND 
(Sacktor et al., 2002). Several of the neurocognitive deficits seen in patients with HAND 
are believed to contribute to HIV risk behavior, affecting impulse control (Lopez, Smith, 
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Meltzer, & Becker, 1999) and episodic memory functions that may impair the ability to 
plan and execute intentions (Woods, Moore, Weber, & Grant, 2009).  
HAND is mostly seen in advanced stages of HIV disease but can occur even in 
PLWH with medically asymptomatic HIV infection (Grant et al., 1987; Heaton, Grant, 
Butters, White, Kirkson, et al., 1995; White, Heaton, & Monsch, 1995). Increased 
duration living with the virus, particularly during the acute phase of infection, has been 
identified as partially responsible for NC impairment. Yet HAND has still been observed 
to varying degrees among PLWH who have been consistently maintained at low-to-
undetectable VLs on ART (Simioni et al., 2010; Tozzi et al., 2007).  
Multiple possible causes of HAND have been suggested: the inability of 
commonly-used ART to penetrate the blood-brain barrier, with reduced levels in the 
central nervous system (CNS) leading to incomplete viral suppression; brain damage 
during acute HIV infection and prior to ART initiation; prolonged inflammatory response 
and CNS immune reconstitution inflammatory syndrome (IRIS); possible neurotoxicity 
of specific antiretrovirals; and exposure to other conditions associated with long-term 
survival with HIV such as vascular dementia, Parkinson’s-related dementia, Alzheimer’s 
disease and depression (Heaton et al., 2011; Johnson & Nath, 2011; Mateen & Mills, 
2012). In addition, it has been suggested that HIV in the brain could develop increased 
adaptation and neurovirulence in the presence of ART over time, potentially spreading to 
other body tissues (Churchill & Nath, 2013). 
Even the mildest form of HAND may be a precursor to more severe NC disorders 
(McArthur, Steiner, Sacktor, & Nath, 2010). HAND in general can present clinically as 
impairment in episodic memory, information processing, attention and executive 
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functions (Woods et al., 2009). Heaton (2011) found that patients in the pre-ART era and 
those with later stage disease had poorer degrees of functioning in multiple NC domains. 
Those in the ART era showed poorer functioning in cognitive domains of memory and 
executive functioning. Visual working memory has been shown to improve with greater 
viral suppression and improved immune function (Gupta et al., 2007). In patients 
presenting with even milder forms of HAND, quality of life can be  affected, with  
struggles  to perform activities of daily living, personal health care management and 
control of  risk behaviors (Malow et al., 2012; McArthur, 2004). In addition to impacting 
risk behaviors and impulsivity, overall NC impairment has been linked with poorer ART 
adherence among PLWH (Hinkin, Castellon, & Durvasula, 2002). Additionally, studies 
have identified impairment in specific domains of functioning — such as verbal memory 
(Applebaum, Reilly, et al., 2009; Wright et al., 2011) and executive functioning (Hinkin 
& Hardy, 2004; Waldrop-Valverde, Jones, Gould, Kumar, & Ownby, 2010) — associated 
with deficiencies in ART adherence. Whereas memory and information processing may 
affect patients’ ability to understand complex medication information, executive 
functioning may impact patients’ ability to make personal medication decisions and 
manage the myriad life complexities that interfere with a treatment regimen. 
Alcohol and other Drug Use 
Studies have reported that more than 50% of HIV-infected clinic-based samples 
reported illicit drug and heavy alcohol use (Bing et al., 2001; Martin et al., 2004; Samet 
et al., 2004). Each additional substance use disorder contributes to poorer health 
outcomes and is associated with decreased access to and use of health care and reduced  
likelihood of being prescribed and/or adhering to ART (Bruce & Altice, 2007).  
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HIV and alcohol abuse are considered to be converging epidemics and, as a result, 
a greater number of individuals are at risk for alcohol use disorders, HIV infection and 
rapid progression to AIDS (Bryant, 2006). Shared high-risk environments and behaviors, 
as well as shared individual characteristics, have contributed to the HIV and alcohol 
abuse epidemics, creating a synergistic phenomenon (Bryant, Nelson, Braithwaite, & 
Roach, 2010; Bryant, 2006). In non-HIV clinic samples, 20-30% of patients are reported 
to have met criteria for past or present alcohol problems (Buchsbaum, Buchanan, Centor, 
Schnoll, & Lawton, 1991; Cleary, Miller, Bush, Warburg, & Delbanco, Aronson, 1988; 
Fleming, Manwell, Barry, & Johnson, 1998).  Furthermore, studies of HIV-infected clinic 
patients have reported that more than 50% reported heavy alcohol use (Martin et al., 
2004; Samet et al., 2004). In a longitudinal cohort study of HIV-positive veterans, 33% 
reported binge drinking and 32% had a clinical diagnosis of alcohol addiction or 
dependence (Justice, Dombrowski, & Conigliaro, 2006).  
Alcohol influences the complex decision-making process to engage in acts that 
place one at risk for acquiring and transmitting HIV and other STIs (Bryant, 2006). Both 
the degree of alcohol intoxication and history of alcohol abuse tend to be associated with 
involvement in more risk behaviors (Bryant, 2006). Alcohol misuse and abuse have other 
deleterious physical and mental health outcomes (Conigliaro, Gordon, McGinnis, 
Rabeneck, & Justice, 2003; Justice et al., 2004) as well as hindering adherence to 
healthcare recommendations, particularly medication regimens (Baum et al., 2010; 
Bryant, 2006; Samet, Horton, Meli, Freedberg, & Palepu, 2004). Research shows that 
severity of alcohol use is correlated with levels of ART non-adherence (Cook et al., 
2001).  
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Several reasons have been cited for the negative impact of active alcohol use on 
ART  adherence (Lucas, Gebo, Chaisson, & Moore, 2002), including: (a) lifestyle 
instability not conducive to ART (Sherer, 1998); (b) poor social support and mistrust of 
the medical establishment (O’Connor, Selwyn, & Schottenfeld, 1994); (c) non-adherence 
to scheduled clinic visits (Lucas et al., 2002); and (d) coexisting mental health disorders 
that act as further barriers to adherence (Batki, Ferrando, Sorensen, & Wall, 1996). HIV-
infected patients have also reported stopping treatment when drinking because of beliefs 
about the toxicity of drinking while on ART (Kalichman et al., 2012; Sankar, 
Wunderlich, Neufeld, & Luborsky, 2007). While there is evidence of combined or 
enhanced toxicity effects, optimal ART adherence remains advised for HIV-positive 
alcohol users (Braithwaite & Bryant, 2000). Although no consistent associations between 
gender and ART adherence have been found, it should be noted that women may be more 
adversely affected by alcohol abuse in terms of ART adherence (Applebaum, Richardson, 
Brady, Brief, & Keane, 2009; Berg & Demas, 2004).  
Alcohol abuse frequently co-occurs with HIV and may further impair NC 
functioning among PLWH, however evidence of interactions between AOD use and HIV 
upon NC performance has varied. Studies have reported that more than 50% of HIV-
infected clinic patients reported heavy alcohol use (Martin et al., 2004; Samet et al., 
2004) and that up to 80% of people with alcohol use disorders may suffer from some 
degree of NC impairment (Bates, Bowden, & Barry, 2002). Among individuals with HIV 
infection and drug and alcohol use disorders, impaired verbal working memory 
(Farinpour et al., 2000), impaired auditory working memory, and enhanced cognitive 
impulsivity have been observed (Martin et al., 2004). Additionally, synergistic negative 
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effects of HIV and heavy alcohol use together have been observed in motor and visual 
spatial tasks (Rothlind et al., 2005). Alcohol use and HIV progression compromise 
information processing, executive functioning, and emotion regulatory functions that may 
be important in adhering to safe sex practices and other preventive behavior (Bryant, 
2006). Alternately, several studies have been unable to identify interactions between drug 
use and HIV upon NC performance (Bornstein et al., 1993; Concha et al., 1992; 
Durvasula, Miller, Myers, & Wyatt, 2001; Selnes, Galai, McArthur, & Cohn, 1997). 
Compounding the direct effects of NC impairment on ART adherence, substance use may 
contribute further to substandard ART adherence (Hinkin et al., 2002; Rothlind et al., 
2005).  
Alcohol use has been shown to play a possible confounding role in the assessment 
of NC impairment among PLWH (Justice et al., 2004). In order to deliver targeted and 
effective clinical care as well as HIV risk reduction and treatment adherence 
interventions, it is important to understand not only specific domains of impairment 
associated with HIV infection and alcohol abuse but also the effects of any potential 
interactions  between these two commonly coexisting conditions.  
Although most research on the use of illicit substances and HIV infection center 
upon injection  drug use, marijuana and cocaine are reported to be the most commonly-
used illicit substances among PLWH (Cook et al., 2001; Korthuis et al., 2008; Kuo et al., 
2004). Substantive evidence has linked general illicit drug use and ART non-adherence 
(Lucas et al., 2006); however, research regarding adherence and marijuana use in 
particular is mixed. Research on medical cannabis use has shown that participants report 
considerable  symptom relief (Prentiss, Power, Balmas, Tzuang, & Israelski, 2004), but 
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several studies indicate that adherence rates are nonetheless lower for marijuana users 
(Corless et al., 2009; Tucker, Burnam, Sherbourne, Kung, & Gifford, 2003). Conversely, 
De Jong et al. (2005) observed greater ART adherence among participants who used 
marijuana medicinally as opposed to recreationally. Research concerning marijuana use’s 
impact on virologic, immunologic and other health markers among PLWH remains 
limited. Research examining psychostimulants such as cocaine and methamphetamines, 
however, has consistently shown an association with decreased adherence (Arnsten et al., 
2002; Hinkin et al., 2007; Tucker et al., 2003). Cocaine use may also be directly 
associated with higher VLs (Arnsten et al., 2002).  
Stressful Life Events 
Life stress is a contextual variable commonly associated with risk and protective 
health behaviors such as ART adherence (Chesney, Morin, & Sherr, 2000). According to 
a 2010 CDC white paper on social determinants of HIV/AIDS in the U.S., distribution of 
power and resources affect environmental conditions such as housing and social support; 
social and physical environments, and availability, cost of, and access to healthcare 
services and contribute as pathways to HIV infection or barriers to overall health 
(Koopman et al., 2000). High levels of perceived stress among PLWH have been 
associated with lower income, and financial difficulty is one of the most frequently 
reported stressful events among PLWH (Mugavero et al., 2009; Reif et al., 2011). Other 
stressful life events are exceedingly common in the lives of PLWH and are negatively 
associated with antiretroviral medication adherence and treatment outcomes.  
Associations between stress and substance abuse also have been identified, but the 
exact relationship remains somewhat elusive. A review of animal studies identified 
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several neurobiological connections between the changes in the brain produced by both 
acute and chronic alcohol and other drug (AOD) use resulting from the introduction of 
stressors (Piazza & Moal, 1998). Identifying relationships between stress and alcohol use 
in clinical settings has been more challenging, in part because of inherent limitations in 
attempting to conduct research with alcoholic participants (Brady & Sonne, 1999; 
Russell, Cooper, Frone, & Peirce, 1999). Patients may vary in their likelihood of drinking 
in response to stress, suggesting that individual factors moderate the relationship between 
stress and alcohol use. However, in some studies, exposure to stressors has been 
consistently associated with increased alcohol use, particularly as an avoidance coping 
mechanism (Brady & Sonne, 1999; Russell et al., 1999). This relationship may indicate 
that, in addition to directly affecting ART adherence, stress may also act through alcohol 
to affect ART adherence.  
Social Support 
Stronger social support is known to reduce one’s reliance on  avoidance coping 
strategies and dampen the effects of stress in some situations (Heaney & Israel, 1997). 
The term “social support” is typically used to describe mechanisms by which 
interpersonal relationships may buffer a person against a stressful environment (Cohen & 
McKay, 1985). Social support is a multidimensional construct and can involve networks 
of individuals providing different modes of support: “(1) emotional support (the 
expression of positive affect, empathetic understanding, and the encouragement of 
expressions of feelings), (2) informational support (the offering of advice, information, 
guidance or feedback), (3) tangible support (the provision of material aid or behavioral 
assistance), (4) positive social interaction (the availability of other persons to do fun 
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things with you), and (5) affectionate support (involving expressions of love and 
affection)”(Sherbourne & Stewart, 1991, p. 707). Researchers have identified these 
modes of support as influential in understanding health behaviors, and have suggested 
that they be matched to the other factors examined in a given study in order to detect a 
relationship (House & Kahn, 1985). For example, if the primary area of social support 
perceived by the participant is “emotional,” its buffering effect may not be observable if 
the actual form of social support needed to achieve an outcome is “tangible” (Cohen & 
McKay, 1985).  
The positive association between social support and adherence to ART regimens 
among PLWH is well documented (Catz et al., 2000; Diiorio et al., 2009; Gordillo, del 
Amo, Soriano, & González-Lahoz, 1999; Holzemer, 1999; Safren et al., 2001; Samet et 
al., 2004; Simoni, Frick, & Huang, 2006; Singh et al., 1999), although few studies have 
focused on specific roles and mechanisms of social support. A meta-analysis found that, 
among people with different diseases, practical support was a much stronger predictor of 
treatment adherence than emotional support (DiMatteo, 2004), but this analysis excluded 
studies that involved substance abusing populations. Further, it has been found that 
emotional support was a stronger predictor of medical care utilization (Broadhead, 
Gehlbach, & Kaplan, 1989) and functional (e.g. financial) support was more closely 
associated with treatment access (Knowlton et al., 2001). One study found that social 
support did not directly influence ART adherence among PLWH, but instead acted 
through the mediators, depression and self-efficacy (Diiorio et al., 2009). Similarly 
Simoni, Frick, and Huang (2006) found that social support operated through affect and 
spirituality in its relationship with efficacy to adhere to ART. Less present in the 
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literature are studies examining the role of social support as a moderator, buffering the 
effects of factors such as substance abuse, NC impairment, and stress on the outcomes of 
ART adherence and response. 
Statement of the Problem 
While there is a greater understanding of HAND and the domains affected by 
HIV, there is also an increasing frequency with which NC impairment is experienced by 
PLWH today. Hence it becomes increasingly important to explore areas of daily 
functioning that are potentially influenced by HAND. The increasing value being placed 
upon ART as treatment and prevention on individual and community levels, both 
nationally and internationally, underscores the importance of exploring the relationship 
between NC impairment and ART adherence in the lives of PLWH. However, health 
behaviors like ART adherence are not enacted in isolation; they are impacted by many 
psychological, biological, and social factors. Complex contributions of common factors 
such as alcohol use, life stress, and social support upon ART adherence must also be 
taken into account. Only from a biopsychosocial perspective can we assess a “real world” 
environment, achieving a broad perspective of the myriad influences on ART adherence 
and service utilization in the lives of PLWH. According to Applebaum (2009, p.455), 
“Given the extent of neuropsychological impairment [among HIV-positive substance 
abusers], future studies should examine the degree to which the impact of 
neuropsychological impairment may moderate interventions for this population, and the 
extent to which skills to cope with neuropsychological problems may boost the potential 
efficacy of such interventions.” 
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Study Aims and Hypotheses 
The overarching question to be answered in this research was:  To what extent do 
psychosocial factors — including neurocognitive impairment, drug use, and alcohol use 
— influence ART adherence, service utilization and VL at baseline and following an 
evidence-based intervention among HIV-positive alcohol abusers? Three study aims and 
accompanying hypotheses were proposed to facilitate answering this question: 
Aim 1 
To determine the degree to which alcohol use, drug use, time from HIV diagnosis 
to treatment, and years living with HIV affect three measures of neurocognitive 
functioning among HIV-seropositive adult alcohol abusers at a single time point. 
? Hypothesis 1a: Greater alcohol, marijuana, and cocaine use will be associated 
with increased neurocognitive impairment. 
? Hypothesis 1b: Living longer with HIV and waiting longer after HIV diagnosis to 
seek treatment will be associated with increased neurocognitive impairment. 
Aim 2 
To explore the degree to which stress, social support and barriers impact ART 
adherence and VL among HIV-seropositive adult alcohol users at baseline.  
? Hypothesis 2a: Greater perceived stress will be associated with higher VL. 
? Hypothesis 2b: Greater social support will be associated with lower VL. 
? Hypothesis 2c: More barriers to adherence will be associated with higher VL. 
? Hypothesis 2d: The above relationships with VL will be partially mediated by 
ART adherence. 
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? Hypothesis 2e: Relationships between psychosocial factors and outcomes of ART 
adherence and VL will be moderated by behavioral and cognitive variables: 
alcohol use, marijuana use and neurocognitive impairment. 
Aim 3 
To evaluate the effectiveness of the adapted Holistic Health Recovery Program 
(HHRP-A) on improving treatment adherence, service utilization and health outcomes 
(VL) among HIV-seropositive adult alcohol users. 
? Hypothesis 3a: Greater improvement in ART adherence, VL, and service 
utilization will be observed in the experimental condition than in the comparison 
condition. 
? Hypothesis 3b: Greater reduction in perceived stress and increase in social 
support will be observed in the experimental condition than in the comparison 
condition. 
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CHAPTER II 
METHODOLOGY 
Using data from a parent study described below, the three following manuscripts 
mirror the three aims already described. Each paper draws from the same parent study, 
but each has a different sample size, utilizes a different set of measures and employs 
different analytic techniques. This dissertation study was approved by the Florida 
International University Institutional Review Board (IRB-13-0072) most recently on 
September 28, 2013. 
Data Source 
To address the research aims proposed in this dissertation, data were analyzed 
from an NIH-funded parent study conducted by Dr. Jessy G. Dévieux (and the late  Dr. 
Robert Malow) titled “Intervening with HIV+ Alcohol Abusers: Influence of Neuro-
Behavioral Factors” (1 R01 AA017405). Their longitudinal (12-month follow-up) 
randomized controlled trial attempted to reduce HIV sexual transmission risk and 
substance use in  370 alcohol-using, HIV+ individuals. The experimental condition 
included an adaptation of the Holistic Health Recovery Program (HHRP), an 
information-motivation-behavioral skills (IMB)-guided, evidence-based intervention for 
improving sexual risk and adherence outcomes for an HIV-positive addicted population 
(Margolin, Avants, Warburton, Hawkins, & Shi, 2003). In this dissertation’s parent study, 
the intervention was adapted for use in a culturally diverse, alcohol-abusing sample. The 
adapted intervention (HHRP-A) is compared to a Health Promotion Comparison (HPC) 
condition, which addresses common health problems, including personal hygiene and 
healthy living.  
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HHRP was developed in recognition of the need to provide an intervention 
sensitive to neurobehavioral problems experienced in this population and was adapted for 
this AOD-abusing population because it is the only CDC-identified intervention for an 
HIV-positive, substance-abusing population that has been shown to reduce HIV 
transmission risk behaviors among PLWH (Margolin et al., 2003). Whereas the original 
HHRP addressed a methadone-maintained, drug abusing population, this adapted version 
was specifically geared toward alcohol users, within an AOD prevention approach. In 
developing HHRP-A, the research team attempted to achieve a reasonable balance 
between maintaining fidelity to the original HHRP and enhancing key characteristics to 
respond to the local context (e.g., community setting, clientele and cultural composition 
or history, resources, priorities). The HHRP intervention had been adapted and evaluated 
in multiple studies among diverse samples of HIV-positive drug users (Anand, Springer, 
Copenhaver, & Altice, 2010; Copenhaver, Bruce, & Altice, 2008; Copenhaver, Lee, 
Margolin, Bruce, & Altice, 2012; Copenhaver & Lee, 2006). 
The primary aims of the parent study were to reduce sex and alcohol-related risk 
behaviors associated with HIV transmission. This dissertation research sought to explore 
secondary aims of the parent study — improving ART adherence and service utilization 
— which were also addressed in the intervention modules.  
Participants 
Recruitment sites were located in densely populated, multicultural, low-income, 
urban areas of South Florida, primarily Miami-Dade County, with high rates of AOD 
abuse, HIV, violence and poverty. The vast majority of the participants were uninsured 
with a disproportionate burden of chronic conditions associated with racial and ethnic 
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health disparities. Thirteen Community-Based Organizations (CBOs) serving the target 
population agreed to act as recruitment sites (see Appendix for list of sites). These CBOs 
were among the largest in the local area providing outpatient AOD abuse treatment 
programs and mental health services to HIV-positive men and women. Recruitment 
settings were selected from a wide range of nonacademic institutions, specialty and 
primary care, public and private facilities as per the National Institutes on Mental Health 
(NIMH) Therapeutic Effectiveness Protocol Development Program. The agencies 
providing outpatient mental health and alcohol and drug abuse treatment shared certain 
attributes: Each program was designed to promote progression from preliminary 
screening and biopsychosocial assessment to individually tailored addiction treatment; 
each program focused on helping patients achieve and maintain abstinence from alcohol, 
drugs, and sexual behaviors through case management and therapeutic activities; and the 
majority of clients at these sites represented families in the lowest socioeconomic class 
and received Medicaid benefits.   
Intervention studies with a public health focus are designed to maximize 
generalizability of findings to broad populations, providers, and settings. They have 
broad sample inclusion and relatively few exclusion criteria.  A total of 370 participants 
meeting inclusion/exclusion criteria were recruited from the study sites between January 
2009 and November 2012. The parent study was designed to maximize generalizability 
of findings to broad populations, providers, and settings by including diverse subgroups 
representative of “real world” settings, and minimizing exclusion criteria. The inclusion 
criteria were: 1) living in Miami-Dade County; 2) being ≥18 and ≤60 years old; 3) being 
HIV-positive and willing to present documentation to confirm serostatus; having 
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consumed any alcohol in the past 3 months; and 4) having a history of alcohol abuse or 
dependence within the past 2 years. Further criteria included: 1) facility in English; 2) 
understanding of the informed consent process; 3) ability to provide contact information 
to be located for more interviews; 4) willingness to be randomized to a treatment or 
control group and to be contacted for follow-up assessments; 5) planning to be in the area 
for the next 12 months; 6) not facing immediate incarceration or residence in a restricted 
environment; and 7) currently not showing overt signs of major psychiatric disorder 
including psychosis or suicidality. In addition to the parent study’s inclusion/exclusion 
criteria, Aims 2 and 3 of this dissertation research also required exclusion of participants 
who had not been prescribed ART. Information regarding ART prescription was 
collected at baseline of the parent study. 
Compensation 
Participants were offered decreasing compensation: $50 gift card for a local store 
upon completing the first assessment; $25 gift card for a local store upon completing 
post-assessment; $15 cash or gift card for attendance at each group session; and $5 cash 
for transportation.  
Group Randomization 
After participants completed the baseline assessment, they were entered into the 
study in cohorts of eight participants of the same gender from across the recruitment 
sites. Using randomized block design, cohorts were assigned to receive either the 
experimental or control condition according to a computer-generated random sequence. 
The random sequencing was expected to control for bias in subject assignments across 
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conditions. Treatment and comparison intervention sessions were scheduled to begin 
when baseline data collection was completed on a group.  
To prevent cross-group contamination, each cohort group was staggered in time and 
space (sessions were scheduled to take place at alternating locations). Since participants 
came from different locations, there was a reduced possibility of cohorts interacting and 
thus discussing their respective experiences on site. 
Treatment Condition: HHRP-A 
HHRP is an interactive, cognitive-behavioral group intervention that includes 
components the CDC has specified as important for HIV-positive transmission risk 
reduction: 1) guided by behavioral theory; 2) focused on HIV transmission risk; 3) 
provided skill building and practice in coping or problem-solving skills; 4) included role-
playing safer sex communication with partners; 5) delivered in settings in which PLWH 
receive services; 6) delivered in an intensive manner; and 7) including issues related to 
coping with HIV status and medication adherence. HHRP-A was guided by IMB Theory 
(Amico, Toro-Alfonso, & Fisher, 2005; Fisher, Fisher, Amico, & Harman, 2006; Starace, 
Massa, Amico, & Fisher, 2006) and contains intervention principles similar to those of 
Cognitive Behavioral Stress Management (CBSM), such as relaxation and coping skills 
training designed to reduce negative mood and slow disease progression. In addition, the 
group-based intervention is designed to promote interaction between participants so that 
they build positive social support networks with peers.  Diffusing risk-reduction 
messages in peer-based social support networks may help to sustain benefits of HIV 
interventions (Latkin and Knowlton, 2006). 
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Group facilitators were staff similar in profile to staff at the CBO recruitment sites, 
per the design of the evidence-based HHRP. Facilitators had a bachelor or high school 
level education and were familiar with the study population. Participants attended eight 
2-hour sessions scheduled twice a week over four consecutive weeks. The HHRP-A 
therapy manual was highly structured, and involves both didactic presentation of material 
and experiential exercise. Content matter was comprehensive in order to address the 
medical, emotional, and spiritual needs of PLWH. Topics addressed by HHRP-A 
included: 1) harm reduction skills training; 2) relapse prevention; 3) training to improve 
emotional, social, and spiritual health, including coping with stigma and grief; 4) 
techniques to increase medication adherence and improve participation in medical care; 
and 5) strategies for making healthy lifestyle choices including reducing HIV sexual 
transmission risk behavior (the original version of the intervention manual can be 
accessed at http://info.med.yale.edu/psych/3s/HHRP_manual.html; fact sheet in 
Appendix). Each session was co-facilitated by two trained counselors using a 
nonjudgmental, motivational enhancing therapeutic style (Miller & Rollnick, 1991). 
Cognitive remediation strategies were incorporated because of the potential for 
cognitive impairment in this population. These strategies included: varied presentation 
modalities; repetition and review; behavioral games; memory books; reduction of 
distraction and fatigue; emphasis on structure and consistency; ongoing assessment of 
new learning and retention, with immediate provision of feedback; and stress 
management (Miller, 1993).  
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Treatment Condition: Health Promotion Comparison  
The proposed randomized design compared the intervention approach of HHRP-
A to a Health Promotion Comparison (HPC) condition. The HPC was not designed to 
provide the IMB-driven techniques of HHRP-A. This condition was meant to be 
educational and didactic, addressing common health problems, personal hygiene, 
nutrition, physical fitness, smoking avoidance/cessation, and healthy living. HPC did not 
incorporate behavioral skills training or motivational enhancement techniques and did not 
promote interaction or social support network development.  HPC matched HHRP- A in 
total administration time and format (eight 2-hour sessions); however this modality was 
condensed and delivered over a period of only two days in order to reduce the risk of 
possible inflated effects in comparison group outcomes as a result of longer-term group 
involvement and attention. As in HHRP-A, HPC was guided by a written manual and 
implemented and held under the same conditions so as to produce equivalent expectancy 
of benefit and to control for effects that could be attributed to nonspecific features of 
HHRP-A.  
A standard care HIV education component was included in the HPC, because it was 
deemed ethically irresponsible not to include some level of HIV education in a 
comparison condition, given the high-risk nature of this population. Thus, the first 
session of the HPC condition included a standard care level of HIV risk reduction, 
approaching what may be considered a “usual” care level that participants might expect 
to receive in a typical CBO program.  
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Data Collection 
 Several data-gathering techniques were utilized depending on the nature/content 
of the instrument, and a wide range of information was covered. Assessment methods 
included: 1) computer-assisted personal interview (CAPI); 2) audio computer-assisted 
self-interview for subjective sensitive topics (ACASI); 3) paper and pen as specified for 
neurological measures.  
Measurement Instruments 
The following instruments were used to measure constructs listed in the three 
aims. Below is a brief description of the measurement instruments. Additional 
information such as reliability and scoring is described in greater detail in the 
manuscripts that follow. 
Years Living with HIV(Aim 1) 
Years living with HIV is a single intake questionnaire item asking the year of HIV 
diagnosis. This value was subtracted from the year of intake to estimate number of years 
living with HIV. 
Time from HIV Diagnosis to Seeking Care (Aim 1) 
Time from HIV diagnosis to seeking care is an ordinal item from the Community 
Programs for Clinical Research on AIDS (CPCRA) asking “How soon after your positive 
test for HIV did you first go for medical care for your HIV?” (Mannheimer, Matts, 
Telzak, & Chesney, 2010).  Response options included: (1) within 6 weeks; (2) 6-12 
weeks; (3) 3-6 months; (4) 6-12 months; (5) more than a year; and (6) I have not gone for 
medical care for my HIV. 
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Alcohol and Drug Use (Aims 1 and 2) 
Alcohol use, marijuana use and cocaine use were assessed using a calendar format 
called time line follow-back (TLFB; Carey, Carey, Maisto, Gordon, & Weinhardt, 2001; 
Weinhardt et al., 1998) to enhance accurate recall and to provide a continuous three 
month history for intensity of drug and alcohol consumption. In Aim 1, these variables 
were measured using three items from the TLFB: total number of “heavy drinking days” 
(defined as ≥ 5 drinks), total number of marijuana use days, and total number of cocaine 
use days. Aim 2 variables were measured by asking the total number of standard drinks 
consumed and total number of times using marijuana in the past 3 months. 
Neurocognitive Instruments (Aims 1 and 2) 
The Auditory Verbal Learning Test, University of California Los Angeles/World 
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) is a test of immediate 
verbal memory capacity, retrieval efficiency, and learning. Fifteen words are read to the 
participant, requesting both immediate and longer-term recall. Scores for immediate 
recall, delayed recall, and percent of words retained can be derived. This study utilized 
the total of immediate recall scores for trials 1-5, with higher scores indicating greater 
functioning.  
The Color Trails Test 2, Form A (CTT2; D’Elia, 1989; D’Elia, Satz, Uchiyama, & 
White, 1996; Lezak, 2004) is primarily a measure of executive functioning, but also 
assesses attention, information processing, psychomotor coordination and speed. CTT-2 
requires the participant to connect encircled numbers 1 through 25, randomly arranged on 
a page, in proper order. CTT-2 shows all numbers twice and the participant must connect 
the numbers from 1 to 25, alternating between pink and yellow circles, disregarding the 
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numbers in circles of the alternate color. This analysis uses the raw time in seconds the 
participant needs to complete the test, with higher scores indicating poorer functioning.  
The Category Test Short Form-Booklet Format (SCT; Halstead, 1947; Wetzel, 
1987) measures executive function, assessing problem-solving ability by requiring the 
examinee to determine the organizing principle behind a series of visually presented 
stimuli, based on the correct or incorrect external feedback from the test administrator. 
This study uses the total raw error score derived, with higher scores indicating poorer 
functioning.  
Barriers to ART Adherence (Aim 2) 
Barriers to adherence is a self-report portion of the CPCRA that includes in its 
ART adherence assessment a section proposing reasons for participants’ missing any 
doses of ART medication with 10 options provided; responses are dichotomous 
(Mannheimer et al., 2002). Options include: “I forget to take my pills;” “I was away from 
home;” and “I am too busy.”  
Social Support (Aims 2 and 3) 
Social support was measured using 19 items from the Medical Outcomes Study 
(MOS; Sherbourne & Stewart, 1991). Questions concerned medical-related quality of life 
and included four functional support scales: emotional/informational, tangible, 
affectionate, and positive social interaction. Each item was rated from (1) “All of the 
time” to (5) “None of the time.” For Aim 2 only four “tangible social support” subscale 
items were used. This functional subscale of the MOS asks the degree to which the 
participant believes s/he have available instrumental help with medical or daily living 
needs. The use of subscales increases sensitivity of the instrument (Sherbourne & 
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Stewart, 1991). The tangible support subscale was selected because of its strength of 
association with medication adherence (Gallant & Block, 1998; Gallant, 2003; Woloshin 
et al., 1993). For Aim 3, the overall social support index (total score) was used, with a 
higher score indicating more support.  
Stress (Aims 2 and 3) 
Stress was measured with 40 items modified from the Life Experiences Survey 
(LES; Sarason, Johnson, & Siegel, 1978) and the Life Events Questionnaire (Cohen et al., 
1983). The first section lists 32 events common to people in a wide variety of situations 
and eight additional items address issues more specific to this population, such as their 
illness and alcohol use. Items were scored on an ordinal scale based upon the degree to 
which participants perceived impact of each event over the past three months. The first 
32 items were two points each and the additional eight items offered three points each. 
Responses to all items were summed for a total stress score (continuous measure) with 
higher scores representing greater stress. 
ART Adherence (Aims 2 and 3) 
ART adherence was measured by the self-reported percentage of time ART 
medications were taken as prescribed over the course of a week, using a portion of the 
Community Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts, 
Telzak, & Chesney, 2010). The adherence score was calculated as the mean of the 
combined total amount of each medication taken during the previous week, according to 
the scale: “all” (100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%) 
(Mannheimer, Morse, John, & Andrews, 2006). In Aim 3, this measure was dichotomized 
as < 95% and ≥ 95% average reported adherence.  
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Viral Load (Aims 2 and 3) 
For Aim 2, documentation of recent RNA VL (collected by participant’s own 
health care provider within one month from study intake) was supplied by the participant 
upon entry into the study. VL was log 10 transformed to accommodate the wide range of 
values for this variable. For Aim 3, VL was a self-report measure using a single question 
from the CPCRA (Mannheimer, Friedland, Matts, Child, & Chesney, 2002; McLellan et 
al., 1992). Participants were asked to “Indicate your viral load the last time it was 
measured” with available responses: (1) undetectable, (2) 50-500, (3) 501-5,000, (4) 
5,001-10,000, (5) 10,001-30,000, (6) 30,001 or more, and (7) don’t know. Self-reported 
measures of VL were significantly correlated with blood measures at baseline. This 
ordinal measure was dichotomized; percent reporting an undetectable VL was reported. 
Service Utilization (Aim 3) 
Service utilization was assessed using a section of the Treatment Services Review 
(TSR) portion of the CSAT-GPRA Client Outcome Measures for Discretionary Programs 
(McLellan et al., 1992; Mclellan et al., 1989). The TSR is an intake instrument designed 
for addictions treatment facilities. The section of the assessment used in this study 
consists of 52 items asking whether the participant is currently or has ever received 
services relevant to HIV-positive substance abusers: screening, recovery services, case 
management services, medical services, after care services, education services, and peer-
based recovery support services. Three additional items from the CPCRA were included: 
1) “Do you receive any financial assistance to buy medications (such as ADAP, Ryan 
White or other government or charitable agency)?”; 2)	  “Is there a clinic, health center, 
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doctor's office, or some other place that you usually go if you are sick or need medical 
care?”; and 3) “Do you have health insurance?”  
Analysis 
Basic descriptive statistics were calculated and reported for all variables in the 
three studies. In order to gain an understanding of the overall degree of NC impairment in 
this sample, single sample t-tests were conducted to compare mean raw NC scores with 
normative scores on each instrument. Norms for NC measures were obtained from 
professional manuals provided for the instruments (D’Elia et al., 1996; Mitrushino, 
Boone, Razan, & D’Elia, 2005; Van der Elst, van Boxtel, van Breukelen, & Jolles, 2005; 
Wetzel, 1987).  Proportions of participants whose scores were 1 or more standard 
deviations below the norm and characteristics associated with this level of impairment 
were reported.  
Aims 1 and 2 were cross-sectional studies, using multivariate linear regression to 
test hypothesized relationships between independent and dependent variables at a single 
time point. When using linear regression for testing baseline, non-recursive models the 
primary assumption is normal distribution of the data; however non-normal data can be 
analyzed with the use maximum likelihood estimation (Kline, 2012). MPlus version 5.1 
was used (Muthen & Muthen, 1998-2012). This software includes functions such as 
robust maximum likelihood framework (MLR) and full information maximum likelihood 
(FIML) to accommodate non-normality, missing data, and distributional issues of the 
data (Yuan & Bentler, 2000). A limited information approach was used to obtain a rough 
approximation of sample size and statistical power, accounting for at least 5% variance in 
the outcome. This technique uses traditional power analysis software to gain a sense of 
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sample size demands (Jaccard & Wan, 1996). Sample sizes in this study were determined 
to yield a satisfactory power coefficient of > 0.95 for linear models with 10 predictors. 
After addressing all diagnostic statistics, the final hypothesized structural equation model 
was analyzed for its overall fit.  
Aim 3 was a randomized controlled trial and analyses were conducted with SPSS 
version 20. Data were assessed for random missingness (MCAR) using Little’s Missing 
Completely At Random Test (Allison, 2001; Little, 1988), and continuous quantitative 
missing values were imputed using the expectation maximization algorithm (Dempster, 
Laird, & Rubin, 1977).	  Change over time on continuous measures was analyzed using 2 
X 3 or 4 repeated measures analyses of variance (ANOVAs) to account for treatment 
condition and time variables. Data not normally distributed were square root transformed. 
Where change over time in any continuous variable was detected, effect sizes (partial η2) 
were reported if significant (Richardson, 2011). For the dichotomous variables, changes 
between each time point were analyzed using McNemar-Bowker tests (Bowker, 1948). 
Dichotomous variables were also cross-tabulated by treatment group at each time point 
using chi-square analyses. Rate ratios (RRs) and 95% confidence intervals (CIs) were 
presented. Significance criteria were Bonferroni-adjusted for number of analyses. 
Missing categorical data were not imputed. Finally, Spearman’s rank correlation between 
baseline adherence and VL at T4 was calculated as a test of veracity and accuracy of the 
self-reported adherence measure (Margolin et al., 2003). Additional Spearman’s rho and 
Pearson correlations between process and outcome variables, as appropriate, were 
calculated.  
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Theoretical Underpinnings 
This three-manuscript style dissertation incorporates elements of different theoretical 
health promotion models. The first manuscript tests a biomedical model. NC outcomes 
are measured in context of their association with non-behavioral factors: exposure to 
factors known to promote NC impairment such as living with HIV, extended time off 
ART, drug use and alcohol use. The second manuscript is a baseline study utilizing a 
biopsychosocial model. This study examines the direct impact of psychosocial factors 
such as stress and social support on a biomedical outcome (VL) and also analyzes this 
relationship through the behavioral mediator of ART adherence. The third manuscript 
evaluates the effects of an intervention guided by the IMB model upon three outcomes: 
ART adherence, service utilization, and VL. Variables thought to act as processes toward 
the development of these outcomes are adopted from the social support stress buffering 
hypothesis.  
Biopsychosocial Model  
George Engel posited in 1977 that humans are biological, psychological, and 
social creatures who may consciously or unconsciously choose behaviors that can 
promote or harm their health (Borrell-Carrio, Suchman, & Epstein, 2004; Engel, 1977). 
The biopsychosocial model was adapted from the General Systems Theory (Bertalanffy, 
1969), which states that all levels of an organization have linked relationships so that a 
change in one level affects changes in others (Mkanta & Uphold, 2006). In a 
comprehensive review of psychosomatic literature, researchers discussed key values 
within the psychosomatic model, proposing that multiple psychosocial factors may 
interact to promote or maintain illness and suggesting to the medical field that 
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interventions utilize not only biomedical but also cognitive, behavioral, and emotional 
strategies in dealing with disease (Novack et al., 2012). This holistic perspective is 
important when considering the recent interest in putting ART treatment to higher  use in 
the prevention of HIV transmission. Not only is HIV transmission a function of 
behavioral, psychological, and cognitive influences, but adherence to treatments that aim 
to reduce VL are equally functions of these interacting factors. 
The biopsychosocial model has been applied to many chronic diseases and several 
areas of HIV research (Mkanta & Uphold, 2006). For example, Hermann et al., (2008) 
suggested that the concept of ART adherence is dynamic and influenced by multiple 
biopsychosocial factors in order to survey the scope and determinants of non-adherence. 
Influential in social work, the biopsychosocial model is most often applied to suggest 
multimodal approaches to care. For example, in linking PLWH with NC impairment to 
care and services, multiple approaches — cognitive, biomedical, and psychosocial — 
have been recommended (Vance & Struzick, 2007). One such approach, a therapeutic 
technique called “cognitive remediation,” is an important feature of the intervention 
examined in Aim 3 of this dissertation study (Miller, 1993). While the model has been 
used to offer a view of service/care utilization as a combination of biologic characteristics 
(e.g., genetic predisposition), psychological factors (e.g., lifestyle, stress), and social 
conditions (e.g., social support) in general medicine (Jones, Edwards, & Gifford, 2002; 
Rock et al., 1996), research using the model in HIV-specific care is lacking. 
Information Motivation Behavioral (IMB) Model 
Several models of health behavior change have been developed to better 
understand the interaction of biopsychosocial factors that influence HIV transmission, 
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prevention, and treatment. One theoretical framework that has effectively predicted HIV 
risk and preventive behavior in diverse samples and conditions is the IMB model (Fisher 
& Fisher, 1992). According to the IMB model, there are three fundamental determinants 
of ART adherence: knowledge of the ART regimen and associated recommendations; 
motivation to maintain ART adherence and low VL; and behavioral skills for performing 
the specific adherence behaviors. This model proposes that ART  adherence information 
(e.g., ART regimen and side effects) and motivation (e.g., attitudes and beliefs about 
adherent and non-adherent behavior), through necessary behavioral skills (e.g., 
medication self-administration and side-effects minimization), will influence adherence-
related health behaviors (Fisher, Amico, Fisher, & Harman, 2008). 
Several empirical tests of the IMB model have been conducted and have 
established the strength of its three major constructs in predicting ART adherence 
(Amico, Toro-Alfonso, & Fisher, 2005; Starace, Massa, Amico, & Fisher, 2006). 
Alternately, the model has not consistently performed in predicting adherence, with 
particular weakness in defining and measuring the “motivation” construct (Amico et al., 
2009; Rongkavilit et al., 2010). Like most models designed to explain health and risk 
behaviors, the IMB model requires precision in the definition of variables to be measured 
(Peltzer, Friend-du Preez, Ramlagan, & Anderson, 2010).  
The IMB model has been tested in a broad range of populations, including college 
students (Fisher, Fisher, Williams, & Malloy, 1994), heroin injectors (Bryan, Fisher, 
Fisher, & Murray, 2000), severely mentally ill adults (Kalichman, Malow, Devieux, 
Stein, & Piedman, 2005), and adolescents (Kalichman et al., 2002). However, the 
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constructs are likely to be most generalizable when applied to a well-defined population 
(Kalichman et al., 2002).  
In applying IMB to ART adherence, Fisher, Fisher, Amico & Harman (2006) 
proposed a model designed to explain adherence behaviors as a function of information 
and motivation operating through adherence behaviors. In their model, the outcome 
behavior of adherence was actually a mediator on the path to health outcomes such as 
CD4 + T-lymphocyte count and VL. This model also suggests that several moderating 
factors, such as mental health and substance use, may impact health outcomes.  
Buffering Hypothesis of Social Support 
Although adherence and VL outcomes have been examined via the Fisher et al., 
(2008) IMB model, additional processes through which these outcomes are hypothesized 
to evolve have been derived from the buffering hypothesis of social support (Cohen & 
McKay, 1985). The buffering model proposes that support protects persons from the 
potentially deleterious impact of stressful events. According to Cohen & McKay (1985), 
an alternative model suggests that social support has a positive effect regardless of 
whether a person is under stress. Evidence for this main effects model can be tested via a 
statistical analysis of support with no stress × support interaction. However, this study 
simply examines each variable’s independent contributions to the outcomes of a 
longitudinal randomized controlled trial. Prior research examining direct impacts of 
social support and the buffering hypothesis has found that both reduction of stress and 
increasing social support are strongly predictive of ART adherence and service utilization 
outcomes (Catz et al., 2000; DiMatteo, 2004; Gonzalez et al., 2004; Mugavero et al., 
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2009; Simoni, Frick, Lockhart, & Liebovitz, 2002; Simoni, Frick, et al., 2006; Wong, 
Sarkisian, Davis, Kinsler, & Cunningham, 2007).  
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CHAPTER III 
TRANSITION TO MANUSCRIPT 1 
This dissertation is written in manuscript style with three publishable articles. To 
adhere to word limits typically expected by journal editors, the manuscripts report only 
the most essential outcomes. It is important to note additional exploration conducted in 
the process of reaching the final model presented in Manuscript 1. These explorations did 
not yield significant outcomes and so, while informative, were not included in the final 
manuscript. 
Latent variable analysis: A strategy of using the three neurocognitive (NC) 
functioning variables (memory, attention and executive functioning) as indicators of one 
latent variable was considered. However, limited information analyses revealed that these 
variables were differentially related to other constructs in the model and this strategy was 
abandoned. It was instead decided to leave the three NC factors as conceptually distinct 
variables. Residual terms for these three factors were instead correlated, based upon 
modifications recommended by the statistical software. 
Testing for moderation: Interaction analyses were pursued to identify and 
examine significant differences in the model path coefficients as a function of duration of 
HIV infection (i.e., duration of HIV was considered the moderator). Product terms were 
introduced into the model for all relevant paths (Jaccard & Turrisi, 2003) and included: 
alcohol use x HIV exposure, marijuana use x HIV exposure, and cocaine use x HIV 
exposure. Single degree of freedom interaction contrasts were performed to compare the 
effects of each drug/alcohol use variable on each of the three NC variables as a function 
of HIV exposure. Although statistically significant interaction contrasts were identified, 
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the decision was made to not interpret these findings because there seemed to be evidence 
of a suppressor effect. Specifically, the path coefficient between reported alcohol use and 
memory variables was positive (greater alcohol use was associated with better memory) 
among those not receiving ART.	  Conversely, the correlation matrix revealed that these 
same variables were marginally correlated in the expected direction (greater alcohol use 
was associated with poorer memory). This reversal provided evidence of a possible 
suppressor effect—i.e. when a moderating variable that has a zero correlation with the 
dependent variable still, paradoxically, contributes to the predictive validity of the 
independent variable. All product terms were excluded from the final model.  
 
Reference 
Jaccard, J., & Turrisi, R. (2003). Interaction Effects in Multiple Regression (2nd ed.). 
Thousand Oaks, CA: Sage Publications. 
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MANUSCRIPT 1: EXPLORING FACTORS ASSOCIATED WITH 
NEUROCOGNITIVE IMPAIRMENT AMONG PEOPLE LIVING WITH 
HIV/AIDS 
ABSTRACT  
Purpose/Aims: Neurocognitive (NC) impairment continues to occur among people living 
with HIV (PLWH). Alcohol and other drug (AOD) abuse may further affect NC 
functioning. This study assesses the degree to which AOD use, time from HIV diagnosis 
to treatment, and years living with HIV affect three areas of neurocognitive functioning 
among HIV-seropositive adult alcohol abusers at a single time point. 
Methods:  The outcome of NC functioning in 370 PLWH living in Miami-Dade County 
was assessed using: the Auditory Verbal Learning Test (AVLT; UCLA/WHO version), 
the Category Test Short Format (SCT), and the Color Trails Test 2 (CTT2) which 
measures several executive functions including information processing. Participants 
reported the number of days using alcohol, marijuana and cocaine over the previous three 
months using a calendar format. Years living with HIV infection was a single item 
continuous measure and time from HIV diagnosis to seeking care was a categorical single 
item measure. A Bivariate linear regression and multivariate linear regression were used 
to test associations between independent and dependent variables.  
Results: Mean scores on NC measures for this population were significantly lower than 
mean normative scores; 39% of participants displayed NC impairment >1 standard 
deviation below normative sample means on >2 NC tests. No significant associations 
were found between alcohol or cocaine use and any NC measure. Marijuana use was 
associated with CTT2 in the bivariate analysis (β=1.031; p=0.007). In multivariate 
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analysis, each day of marijuana use and year living with HIV were associated with a .32 
(p=0.05) point and 1.18 (p=0.03) point poorer performance score on the CTT2, 
respectively. 
Conclusion: Outcomes from this study suggest that both marijuana use and duration of 
HIV infection may impair cognitive functioning among PLWH in ways that may impair 
their ability to follow important treatment recommendations. 
Key Words: HIV, neurocognitive, alcohol, marijuana, cocaine 
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INTRODUCTION 
Since the introduction  of highly active antiretroviral therapy (ART), the 
incidence of HIV-associated dementia has declined from 10%-15% to rates of 2%-5% of 
people living with HIV (PLWH; Heaton et al., 2010; Robertson et al., 2007; Sacktor, 
2002). However, milder forms of HIV-associated neurocognitive disorders (HAND) have 
been reported in up to 40% of this population, in part because HIV-positive individuals 
are living longer with the disease (Antinori et al., 2007; Durvasula, Norman, & Malow, 
2009; McArthur, 2004; Sacktor, 2002; Sacktor et al., 2007).  
HAND, ranging from asymptomatic neurocognitive impairment to profoundly 
disabling HIV-associated dementia (Antinori et al., 2007), are mostly seen in advanced 
stages of HIV disease but can occur even in PLWH who have medically asymptomatic 
HIV infection (Grant et al., 1987; Heaton et al., 1995; White, Heaton, & Monsch, 1995). 
While increased exposure to the virus, particularly during the acute phase of HIV 
infection, is associated with  neurocognitive (NC) impairment, HAND has  been observed 
to varying degrees even among PLWH who have consistently maintained low-to-
undetectable viral loads on ART (Simioni et al., 2010; Tozzi et al., 2007).  
HAND  can express clinically as impairment in episodic memory, information 
processing, attention, and executive functions (Woods et al., 2009). In patients presenting 
with even milder forms of HAND, quality of life can be greatly affected, with individuals 
suffering from difficulties in ability to perform activities of daily living, personal health 
care management, medication management and controlling risk behaviors (Hinkin et al., 
2002; Malow et al., 2012; McArthur, 2004).  
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Abuse of alcohol and other drugs frequently co-occurs with HIV and may further 
impair NC functioning (Substance Abuse and Mental Health Services Administration, 
2011; Volkow, 2012). More than 50% of HIV-infected patients in clinic-based samples 
have reported illicit drug and heavy alcohol use (Bing et al., 2001; Martin et al., 2004; 
Samet et al., 2004) with marijuana and cocaine reported as the most commonly used 
illicit substances among PLWH (Cook et al., 2001; Korthuis et al., 2008; Kuo et al., 
2004). Negative effects of HIV and heavy drug or alcohol use together have been 
observed to affect synergistically NC functioning and the progression of HAND 
(Anthony, Arango, Stephens, Simmonds, & Bell, 2007; Nath, Maragos, Avison, Schmitt, 
& Berger, 2001; Rothlind et al., 2005). Among individuals with HIV infection and drug 
and alcohol use disorders, impaired verbal working memory, impaired auditory working 
memory, and enhanced cognitive impulsivity have been observed (Farinpour et al., 2000; 
Martin et al., 2004). These cognitive functions are associated with the higher-order 
thinking required to conduct safer sex practices and health management behaviors such as 
ART adherence (Bryant, 2006; Hinkin et al., 2002; Meade, Conn, Skalski, & Safren, 
2011; Rothlind et al., 2005).  
Abuse of alcohol and other drugs has been shown to play a possible confounding 
role in the assessment of NC impairment among PLWH (Justice et al., 2004). In order to 
deliver targeted and effective clinical care, as well as HIV risk reduction and treatment 
adherence interventions, it is important to understand specific domains of impairment 
associated with exposure to HIV and the use of commonly abused substances such as 
alcohol, marijuana and cocaine. By testing a biomedical model with structural equation 
modeling, this study seeks to explore direct relationships between exposure to HIV and 
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degree of alcohol and drug use upon several major domains of NC functioning including 
memory, information processing, attention, and executive function.  
 
METHODS 
Study Design 
This study employed a cross-sectional design, utilizing baseline data gathered 
between 2009 and 2012 as part of a prospective randomized controlled trial for HIV-
positive, adult alcohol users (R01 AA017405). Participants (N=370) were recruited from 
13 community-based organizations in densely populated, multicultural, low-income areas 
of Miami-Dade County, Florida with high rates of alcohol use and HIV. The inclusion 
criteria were: being 18 to 60 years old; being HIV-positive; having consumed any alcohol 
in the past 3 months; and having a history of alcohol abuse or dependence within the past 
2 years. Further criteria included facility in English, ability to understand the informed 
consent, planning to be in the area for the next 12 months, and currently not showing 
overt signs of any major psychiatric disorder, including psychosis or suicidality. 
Several data-gathering techniques were utilized depending on the nature and 
content of the instrument being administered. Assessment methods consisted of: 1) 
computer-assisted personal interview (CAPI); 2) audio computer-assisted self-interview 
for subjective sensitive topics (ACASI); 3) paper and pen as specified for neurological 
measures and time line follow back (TLFB).  
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Measures: Independent Variables 
“Years living with HIV” was measured as a single intake questionnaire item 
asking the year they received their first HIV-positive test. This value was subtracted from 
the year of intake to calculate number of years living with HIV.  
Time from HIV diagnosis to seeking care was  an ordinal item from the 
Community Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts, 
Telzak, & Chesney, 2010) asking “How soon after your positive test for HIV did you first 
go for medical care for your HIV?” Response options were: (1) within 6 weeks; (2) 6-12 
weeks; (3) 3-6 months; (4) 6-12 months; (5) more than a year; and (6) I have not gone for 
medical care for my HIV. This final response option did not provide an interval time 
measurement. Two participants selecting option (6) had been diagnosed at least one year 
before interview and were classified as option (5) and one participant had been diagnosed 
recently so this response was coded as “missing.”  
Alcohol use, marijuana use and cocaine use were assessed by TLFB using a 
calendar format to enhance accurate recall and to provide a continuous three-month 
history for intensity of drug and alcohol consumption. These variables were measured 
using three items from the TLFB: total number of “heavy drinking days” (defined as ≥ 5 
drinks), total number of marijuana use days, and total number of cocaine use days. Up to 
three months’ recall of alcohol and other drug use has proved to provide reliable data 
(Schroder, Carey, & Vanable, 2003). TLFB has strong agreement with other measures of 
AOD use and has reliability measures ranging from 0.75 to 0.90 (Fals-Stewart, O’Farrell, 
Freitas, McFarlin, & Rutigliano, 2000).  
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Measures: Dependent (Outcome) Variables 
A battery of three neuropsychological tests was administered to derive scores in 
various cognitive domains, including memory and executive functions. These domains 
were selected for importance to the parent study intervention and outcomes in this study. 
For example, executive functions assess  problem-solving skills and the ability to change 
behavior based on external feedback, whereas information processing and memory are 
related to comprehending, retaining, and applying instructions such as medical advice  
and medication dosing (Lezak, 2004). The tests selected have been used in previous 
studies with HIV-positive users of alcohol, marijuana and cocaine (Di Sclafani, Tolou-
Shams, Price, & Fein, 2002; Durvasula et al., 2001; Maj et al., 1994; Mason et al., 1998; 
Messinis, Kyprianidou, Malefaki, & Papathanasopoulos, 2006; Rothlind et al., 2005) and 
have well-developed norms, high reliability and high validity (Basso & Bornstein, 2000; 
Bono et al., 1996; Selnes et al., 1997; Stern, Silva, Chaisson, & Evans, 1996). Raw NC 
scores were analyzed; unadjusted NC measures provide better ecological validity when 
scores are not intended to diagnose “impairment” in the sample (Silverberg & Millis, 
2009).  
The Auditory Verbal Learning Test, University of California Los Angeles/World 
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) measures immediate 
verbal memory capacity, retrieval efficiency, and learning. Fifteen words were read to the 
participant, requesting both immediate and longer-term recall. Scores for immediate 
recall, delayed recall, and percent of words retained can be derived. This study utilized 
the total of immediate recall scores for trials 1-5, with higher scores indicating greater 
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functioning. This instrument demonstrated high test-retest reliability, with alpha scores 
ranging from 0.51 to 0.72 (Lezak, 2004).  
The Color Trails Test 2, Form A (CTT2; D’Elia, 1989; D’Elia, Satz, Uchiyama, & 
White, 1996; Lezak, 2004) is primarily a measure of attention, cognitive flexibility, 
information processing, and psychomotor speed. CTT-2 requires the participant to 
connect encircled numbers 1 through 25, randomly arranged on a page, in proper order. 
In addition to measuring functions of attention and information processing, this 
instrument adds elements of mental flexibility and response inhibition. CTT-2 shows all 
numbers twice, and the participant must connect the numbers from 1 to 25, alternating 
between pink and yellow circles, disregarding the numbers in circles of the alternate 
color. This analysis uses the raw time in seconds the participant needs to complete the 
test, with higher scores indicating poorer functioning. The CTT-2  was developed for the 
World Health Organization multicenter study of HIV infection (D’Elia, Satz, Uchiyama 
& White, 1996). The test is sensitive to a variety of neurological impairments and 
processes (Tombaugh, 2004) and, because it is entirely numeric and requires no language 
skills, it is considered culturally unbiased (Maj et al.,1994). Additionally, the instrument 
has shown strong agreement with other cognitive assessments among PLWH (Maj et al., 
1993; Maj et al.,1994) and has displayed good temporal stability with test-retest 
reliability between 0.85-1.00 (D’Elia et al., 1996).  
The Category Test Short Form-Booklet Format (SCT; Halstead, 1947; Wetzel, 
1987) measures executive function, assessing problem-solving ability by requiring the 
examinee to determine the organizing principle behind a series of visually presented 
stimuli, based on the correct or incorrect external feedback from the test administrator. 
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This study uses the total raw error score derived, with higher scores indicating poorer 
functioning. Test-retest coefficients have varied from 0.60 to 0.96 depending upon the 
severity of impairment in the sample (Wetzel L, 1987). 
A hypothesized directional model was constructed to assess the degree to which 
independent relationships exist between HIV exposure, alcohol use, marijuana use and 
cocaine use on the outcome of NC functioning as indicated by three different cognitive 
performance measures. Because advanced age is the most common predictor of 
deterioration in NC functioning, analyses of duration of HIV infection were controlled 
for age in the model (see below). 
Analytic Strategy 
Descriptive statistics were calculated for all of the variables in the model. Means, 
standard deviations, skewness and kurtosis levels were calculated for all continuous 
variables; frequencies were generated for dichotomous and categorical variables. In order 
to gain an understanding of the overall degree of NC impairment in this sample, one-
sample t-tests were used to compare mean raw NC scores with normative scores on each 
instrument. Raw scores were square root transformed and confidence intervals represent 
the difference between the raw, transformed scores and square roots of the normative 
scores. Norms for NC measures were obtained from professional manuals provided for 
the instruments (D’Elia et al., 1996; Mitrushino, Boone, Razan, & D’Elia, 2005; Van der 
Elst, van Boxtel, van Breukelen, & Jolles, 2005; Wetzel, 1987). Raw NC scores were 
used in bivariate and multivariate regression analyses; age, gender and educational level 
were entered as covariates. Bivariate regression analyses assessed relationships between 
each independent and dependent variable using SPSS version 21. NC scores were square 
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root transformed to adjust for non-normality for t tests and robust Maximum Likelihood 
framework was invoked in MPlus version 5.1 to accommodate non-normality in the 
multivariate analysis (Yuan & Bentler, 2000). Missing data bias was assessed by 
computing a dummy variable reflecting the presence or absence of missing data for each 
variable, which was correlated with all other variables in the model, as well as 
demographic variables. No correlations between dummy variables for missing data and 
all other variables in the model were statistically significant, suggesting that data were 
most likely missing at random. With no systematic patterns observed in the missing data, 
a full information maximum likelihood (FIML) method was used to accommodate the 
missing data. A limited information approach was used to approximate sample size and 
statistical power, accounting for at least 5% variance in the outcome (Jaccard & Wan, 
1996). To assess non-model-based outliers, leverage indices were examined for each 
participant based on their multivariate profile for the variables included in the model 
analyses. An outlier was defined as an observation with a leverage score four times 
greater than the mean leverage. The mean leverage score across participants was 0.09. 
Based on the criteria described above, no outliers were evident in the sample data. After 
addressing all diagnostic statistics, the final hypothesized model was analyzed using 
Mplus software version 5.1 (Muthen & Muthen, 2008); strengths of association were 
reported. 
 
RESULTS 
The mean age of participants was 44.79 years; most (63.5%) were men and 
identified as black (76.2%). Most (55.7%) of participants reported at least high school 
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completion; however few (8.2%) were employed. The mean number of years living with 
HIV was 12.2. While most (58.4%) sought treatment within 6 weeks of receiving a 
positive HIV test, 24.6% of participants waited over a year before seeking care (Table 
1.1). Although not included in the tested model, the majority (76.7%) reported that they 
were currently taking ART; 80% reported perfect (100%) treatment adherence; and 45% 
had an undetectable viral load when last tested. 
Single sample t-tests comparing the mean raw NC scores with normative scores 
on each instrument showed that measures of memory, executive functioning, and 
information processing for the study group  were significantly poorer (all p<0.001) than 
those observed in healthy samples as follows: AVLT, t=-16.25 [95% CI = -0.67, -0.52]; 
CTT2, t=6.65 [95% CI = 0.53, 0.97]; and SCT, t=11.52[95% CI = 0.66, 0.93]. Over a 
third (39%) of the study population  scored at least one standard deviation below the 
mean for normative samples on at least two NC tests, consistent with clinically 
significant NC impairment (Antinori et al., 2007).  
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Table 1.1 (1). Sociodemographic characteristics of participants at baseline (N=370) 
 
 
Mean (SD)  
N (%) 
Skewness / 
Kurtosis 
Age 44.79 (7.3) -0.56 / -0.13 
Gender (Male) 233 (63.5%) -0.56 / -0.69 
Hispanic Ethnicity (Yes) 53 (15%) 1.97 / 1.90 
Race   
Black 266 (76.2%) -1.24 / -0.47 
White 50 (14.3%) 2.05 / 2.20 
Years education  0.41 / -0.17 
<8th grade 29 (8.2%) - 
Some high school 128 (36.1%) - 
HS diploma 109 (30.7%) - 
Some college/tech 71 (20%) - 
College degree 15 (4.2%) - 
Graduate training 3 (0.8%) - 
Employed (Yes) 29 (8.2%) 3.07 / 7.45 
Years since HIV diagnosis 12.15 (7.5) 0.20 / -1.01 
Time from HIV Diagnosis to     
Treatment   
 0.65 / -1.41 
Within 6 weeks 206 (58.4%) - 
6 – 12 weeks 13 (3.7%) - 
3 – 6 months 22 (6.2%) - 
6 months – 1 year 25 (7.1%) - 
1 year + 87 (24.6%) - 
Taking ART (Yes) 273 (76.7) -1.27 / -0.40 
Days using in last 3 mos.    
Alcohol  15.77 (23.33) 1.86 / 2.83 
Marijuana 9.29 (20.68) 2.84 / 7.59 
Cocaine 15.68 (23.89) 1.89 / 2.80 
Neurocognitive Functioning   
CTT2 116.31 (49.82)* 1.71 / 4.97 
 SCT 38.09 (15.58)* -0.38 / -0.86 
AVLT 43.44 (9.63)* -0.03 / -0.22 
* Raw scores reported. All sample means are significantly different from normative sample at p<0.01.  
Normative scores used for comparison testing represented mean age and education for this sample. 
Skewness and kurtosis values for neurocognitive instruments reflect distribution of scores prior to square 
root transformation. 
 
 
Bivariate analyses (Table 1.3) identified one significant relationship. Marijuana 
use was associated with a poorer scores on the CTT2 (β=1.031; 95% CI: 0.285, 1.777; 
p=0.007). After examining diagnostics for normality, outliers and patterns of missing 
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data, the final model was tested. Figure 1.1 presents both significant and non-significant 
path coefficients of the final model. The straight lines with arrows from observed 
variables represent presumed pathways of association, and the values along the pathways 
are unstandardized path coefficients. All exogenous variables were assumed to be 
correlated. Unstandardized path coefficients, standard errors and 95% confidence 
intervals are listed in Table 1.4. Following modification indices, it was decided to 
correlate residual terms (i.e. error variance) between three measures of NC functioning. 
Focused fit indices did not show evidence of Heywood cases. Standardized residual 
values were <2. Focused fit indices suggested satisfactory model fit after correlating error 
terms. The final model explained 8% of variance in memory, 7% of variance in 
information processing, and 4% of variance in executive functions. When examining the 
model, two associations approached or achieved statistical significance. On average, for 
each day of marijuana use, the CTT2 score increased by 0.32, indicating poorer 
performance on this NC measure. Similarly, on average, each year living with HIV 
increased the CTT2 score by 1.18.  
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Figure 1.1 (1). Significant regression paths among measured variables in the structural 
equation model among HIV-positive alcohol abusers (N=370) 
 
*Significant at p<0.05 
Regression coefficients (represented as one-way arrows) are unstandardized. 
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Table 1.2 (2). Bivariate regression statistics, 95% confidence intervals, and p-values (N=370) 
  β 95% CI P 
Alcohol Days1 AVLT6 -0.005 -0.049, .039 0.82 
CTT27 -0.137 -0.386, 0.111 0.28 
SCT8 -0.017 -0.089, 0.056 0.65 
Marijuana Days2 AVLT 0.009 -0.044, 0.063 0.73 
CTT2 0.275 -0.024, 0.573 0.07 
SCT -0.049 -0.137, 0.038 0.27 
Cocaine Days3 AVLT 0.011 -0.032, 0.053 0.63 
CTT2 -0.172 -0.413, 0.069 0.16 
SCT 0.027 -0.033, 0.097 0.46 
Years of HIV 
Infection4 
AVLT -0.075 -0.208, 0.059 0.27 
CTT2 1.031 0.285, 1.777 0.007 
SCT 0.096 -0.124, 0.316 0.39 
Time from HIV 
Diagnosis to 
Seeking Medical 
Care5 
AVLT -0.045 -0.570, 0.480 0.87 
CTT2 0.384 -2.509, 3.277 0.79 
SCT -0.333 -1.192, 0.526 0.447 
1Number of days using alcohol in past 3 months 
2Number of days using marijuana in past 3 months 
3Number of days using cocaine in past 3 months 
4Duration of known HIV infection in years 
5Time interval from diagnosis of HIV infection to seeking medical care.  
6Auditory Verbal Learning Test 
7Color Trails Test 2 
8Short Category Test  
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Table 1.3 (3). Unstandardized path coefficients, standard errors, 95% confidence 
intervals, and p-values (N=370) 
 Coefficient SE 95% CI P 
Alcohol Days1 AVLT6 -0.01 0.03 -0.07, 0.51 0.79 
CTT27 -0.05 0.16 -0.36, 0.26 0.75 
SCT8 0.02 0.04 -0.06, 0.11 0.59 
Marijuana Days2 AVLT 0.03 0.04 -0.05, 0.11 0.45 
CTT2 0.32** 0.17 -0.001, 0.65 0.05 
SCT -0.01 0.06 -0.13, 0.10 0.82
Cocaine Days3 AVLT 0.00 0.03 -0.05, 0.06 0.94 
CTT2 -0.13 0.14 -0.40, 0.15 0.37 
SCT 0.02 0.05 -0.07, 0.11 0.65 
Years of HIV 
Infection4 
AVLT -0.04 0.10 -0.23, 0.15 0.66 
CTT2 1.18* 0.54 0.12, 2.25  0.03 
SCT 0.14 0.15 -0.17, 0.44 0.37 
Time from HIV 
Diagnosis to 
Seeking Medical 
Care5 
AVLT 0.18 0.38 -0.56, 0.92 0.63 
CTT2 -1.77 2.33 -6.34, 2.79 0.45 
SCT -0.48 0.61 -1.68, 0.44 0.43 
1 Number of days using alcohol in past 3 months 
2 Number of days using marijuana in past 3 months 
3 Number of days using cocaine in past 3 months 
4 Duration of known HIV infection in years 
5 Time interval from diagnosis of HIV infection to seeking medical treatment.  
6 Auditory Verbal Learning Test 
7 Color Trails Test 2 
8 Short Category Test 
*Significant at p<0.05 
**Approaching significance 
DISCUSSION 
This study found that NC impairment was common (39%) in this group. Other 
U.S. studies of HIV-seropositive adults using similar NC measures have yielded different 
results. A U.S. study of adult PLWH found their participants scored lower on CTT2 (  
=100.1) than participants in this study (Ammassari et al., 2004). Another study of HIV-
seropositive African American men also reported significantly lower CTT2 scores with 
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mean score of 93.09 for their HIV+ symptomatic group (Richardson et al., 1999). These 
higher functioning levels could be explained by their samples’ lower mean age and AOD 
use characteristics. 
Two variables—more frequent marijuana use and prolonged duration of HIV 
infection—were associated with poorer performance on one NC measure. Higher number 
of days of marijuana use predicted poorer performance on the CTT2, which measured 
frontal systems functioning such as attention, executive functions and information 
processing (D’Elia et al., 1996; Horton Jr, 1979). Although significant differences in 
CTT2 scores have been identified between HIV-positive intravenous drug users and non-
users (Starace et al., 1998), previous research on the NC effects of marijuana use has 
yielded mixed results. Most studies examining marijuana-associated NC functioning 
found long-term use to impede performance in domains of executive functions, verbal 
memory and psychomotor speed (Bolla, Cadet, & London, 1998; Gonzalez, Carey, & 
Grant, 2002; Messinis et al., 2006). While it is believed that chronic illicit drug use can 
exacerbate NC sequelae of HIV infection (Anthony, Arango, Stephens, Simmonds, & 
Bell, 2008; Basso & Bornstein, 2000; Norman, Basso, Kumar, & Malow, 2009), little 
actual exploration of long-term cognitive impact of marijuana use has been conducted 
among PLWH. One study by Cristiani, Pukay-Martin, & Bornstein (2004) reported  a 
significant association between marijuana use and poorer NC functioning among PLWH 
with more advanced disease. These effects were most profound in the area of memory 
performance.  
Methodological issues associated with NC assessments and the classification of 
acute versus non-acute effects of marijuana use should be considered when interpreting 
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these and similar study outcomes (Gonzalez et al., 2002). In this study, a three-month 
drug use history was collected with no control for any recent period of drug abstinence; 
thus, marijuana use was believed to be continuous and NC performance measures may 
have actually measured acute or intoxication effects of marijuana. Additionally, only 
associations with performance on the CTT2 measure were significant; however, this 
instrument may measure several domains of functioning, including psychomotor speed 
attention (D’Elia et al., 1996). Without the corroboration of results of testing using 
instruments measuring similar NC domains, the exact areas of neuropsychological impact 
associated with marijuana use cannot be determined with certainty.  
An additional finding of this research was that the number of years living with 
HIV predicted poorer performance on the CTT2 instrument. Although the introduction  
of ART has significantly reduced incidence of severe NC disorders, particularly 
dementia, among PLWH,  evidence of milder HAND is common even among virally 
suppressed patients (McArthur et al., 2010). In this sample, no significant association was 
found between NC functioning and the length of time from HIV diagnosis to seeking 
care. It should also be noted that the patients evaluated in this study were heterogeneous 
in ART treatment and viral suppression.  
Moreover, there was a high prevalence (39%) of clinically significant NC 
impairment. There are several possible explanations for the poorer NC functioning 
observed to be a function of time living with HIV in this study and not necessarily as a 
function of delayed ART initiation. An inflammatory response can occur when immune 
functioning rebounds after treatment with ART immune reconstitution inflammatory 
syndrome (IRIS). However, regardless of possible IRIS, greater immunosuppression 
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remains a strong predictor of NC impairment among PLWH (Gupta et al., 2007; Heaton 
et al., 2010); thus early initiation of ART is reported to be one of the most important 
preventive measures against developing HAND (Müller et al., 2010; Tozzi et al., 2007). 
Continuous ART adherence is also a protective factor against NC impairment (Hinkin et 
al., 2002). While some participants in this study may have initiated treatment early, only 
77% of participants in this group report currently taking ART. It is also possible that the 
association found between years living with HIV and poorer CTT2 performance may be a 
function of age-related cognitive decline (Mateen & Mills, 2012); although the analyses 
were controlled for age, older age remains a strong predictor of NC impairment, and is 
highly correlated with duration of HIV infection.  
Certain limitations of this study are important to note. These participants were 
drawn from clinical sites and may not be representative of PLWH not receiving 
drug/alcohol addiction or HIV treatment. Reporting bias should also be considered in 
interpreting outcomes. Nearly a quarter of the study population  was in abstinence-based, 
residential addiction treatment at the time of this study, and it is possible that recent 
substance use was underreported, and/or that answers reflected months of abstinence in 
the treatment center. Moreover, underreporting may have varied by substance; marijuana 
use is likely to be less stigmatized than cocaine use (Flom et al., 2001) and possibly less 
than alcohol use. Additionally, this is a cross-sectional analysis; not only is it impossible 
to infer causality, but participants were heterogeneous and at different stages of care for 
HIV and drug and/or alcohol treatment. Measurement issues should be considered when 
interpreting this study’s results. Only three NC instruments were used; however, HIV or 
drug/alcohol use can affect many other cognitive functions not evaluated here, such as 
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psychomotor speed and coordination, prospective memory, and cognitive impulsivity 
(Reger, Welsh, Razani, Martin, & Boone, 2002; Schuster & Gonzalez, 2012; Woods et 
al., 2009). The NC instruments used were, however, commonly utilized in similar 
research and considered to be reliable. Of greater concern is that poor mean NC scores 
for this group may also suggest poorer recall on self-report measures. 
Finally, the construct validity of some study measures should be taken into 
account. As mentioned, the CTT2 may be evaluating several domains of cognitive 
functioning, reducing the ability to pinpoint exact areas of impairment. In addition, the 
item assessing amount of time from HIV diagnosis to seeking care did not provide 
information on actual time to ART initiation. This item was intended as a measure of care 
utilization; however, for the purpose of this study, the measure was used as a proxy for 
ART initiation—i.e. one who sought care sooner might also be treated with ART sooner.  
Counter to reports that cocaine and alcohol use exacerbate NC impairment among 
PLWH (Nath, 2010), this particular study did not find such associations. Because abuse 
of alcohol and illicit substances is inextricably linked to HIV (Volkow, 2012), further 
investigation into interaction effects between long-term drug/alcohol use and HIV is 
recommended. Further, future research should consider the contributions of substance use 
to overall NC functioning for the delivery of clinical care and health behavior 
interventions. Early HIV care can help decrease potential NC impairment and yield better 
health outcomes for HIV-infected populations; however people suffering from substance 
use disorders or cognitive impairment may find it difficult to follow important medical 
recommendations (Baum et al., 2010; Braithwaite & Bryant, 2010; Bryant, 2006; Cook et 
al., 2001; Hinkin, Castellon, & Durvasula, 2002; Rothlind et al., 2008). Outcomes from 
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this study provide further evidence of the prevalence of NC impairment that can help to 
guide and enhance interventions for PLWH who use alcohol and drugs. The delivery of 
health interventions and clinical care should consider taking a harm-reduction approach: 
working with the patient’s current substance use status to improve HIV treatment 
adherence and service utilization and delivering interventions and services that are 
sensitive to cognitive difficulties (Margolin, Avants, Warburton, & Hawkins, 2002; 
Margolin et al., 2003; Miller, 1993).  
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CHAPTER IV 
TRANSITION TO MANUSCRIPT 2 
Manuscript 2 tested a model proposing associations between psychosocial factors 
on the outcome VL, mediated by ART adherence. Features of this study drew from 
results found in Manuscript 1. Latent variables were not considered in the structural 
equation model, so all variables were single-measure items. Cocaine was removed from 
the analysis, because fewer participants reported using this drug and because no 
significant associations were identified with cocaine in the first study. Although the three 
NC measures did not load sufficiently to create a latent variable, they were all retained in 
the analysis because each one measures unique domains of functioning. 
This study used structural equation modeling to test the biopsychosocial model, 
evaluating direct effects of independent and interaction variables on two dependent 
variables, VL and ART adherence. A biomedical model such as that tested in manuscript 
1, addresses only associations of factors known to have direct biological impact upon 
health (e.g. the association of taking insulin upon blood sugar levels); whereas a 
biopsychosocial model tests associations between psychological and social factors—such 
as stress and social support—upon a biomarker or measurable health outcome.  
Upon originally testing these relationships, interaction effects were identified 
between social support and marijuana on VL and between barriers and marijuana on ART 
adherence. However, after eliminating 27 non model-based outliers (9.9% of participants) 
from the analysis, these interaction effects became non-significant. To assess non-model-
based outliers, leverage indices were calculated for each participant based on their 
multivariate profile for the variables included in the model analyses.  The leverage score 
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is based on how much the observation's value on the predictor variable differs from the 
mean of the predictor variable. The greater an observation's leverage, the more potential 
it has to be an influential observation. A leverage score four times greater than the mean 
leverage indicated presence of outliers (Jaccard & Wan, 1996). Only cases with outliers 
that were statistically impossible—either due to misreporting or data entry error—were 
removed. Model was analyzed with and without outliers – results were substantively the 
same.  However, given that outliers can bias parameter estimates the decision was made 
to trim the outliers for the final model (Aguinis, Gottfredson, & Joo, 2013). The 
identification of marijuana as a potential moderator should be noted for future study.  
Model-based outliers were examined using limited information regression 
analyses for each of the linear equations generated by the various paths included in the 
model tested. Each endogenous variable was regressed onto the indicators of the 
exogenous predictor variables. DfBeta is the change in the regression coefficient that 
emerges after that case is deleted. An outlier was defined as an individual who had a 
dfBeta three times larger than the standard error of a coefficient (> 1.0). No model-based 
outliers were evident in these analyses. 
In the biopsychosocial model, psychosocial factors are hypothesized to directly 
affect a biomedical health outcome. Taking medication would not necessarily be included 
as a mediator in this model; however, possible partial mediation by ART adherence 
seemed to be an essential role to consider in a model attempting to explain VL. This 
exploration was conducted because of the abundance of research supporting the 
importance of ART adherence for positive health outcomes among PLWH. 
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MANUSCRIPT 2: TESTING A MEDIATED BIOPSYCHOSOCIAL MODEL TO 
PREDICT VIRAL LOAD AMONG PEOPLE LIVING WITH HIV 
ABSTRACT 
Purpose/Aims: Antiretroviral therapy (ART) adherence is associated with improved 
HIV-related health outcomes, whereas inadequate treatment adherence predicts increased 
mortality, viral replication, and increased risk of transmitting the virus to others. 
Neurocognitive (NC) impairment, drug and alcohol abuse, and psychosocial factors such 
as stress all have been associated with poorer adherence, while social support has 
predicted better adherence rates. This study sought to explore the degree to which stress, 
social support and ART adherence barriers impact viral load (VL) via ART adherence 
among HIV-seropositive adults.  
Methods: This study used multivariate linear regression modeling using Mplus to test a 
mediated biopsychosocial model predicting VL among a cross-sectional sample of 246 
HIV-positive adults who were on ART. Exogenous variables were tangible social 
support, barriers to ART adherence, and stress. Moderators were alcohol use, marijuana 
use and NC impairment. The mediator was ART adherence. Baron and Kenny’s four-step 
approach was used to test mediation. 
Results: A small positive association between marijuana use and adherence approached 
significance (β=0.15, p=0.057). Each additional barrier predicted a 10% decrease in 
adherence rates and a 0.42-unit increase in log10 VL. No interaction effects were 
identified. The relationship between barriers to adherence and log10VL was partially 
mediated by ART adherence. 
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Discussion: These findings provide modest support for the biopsychosocial model in 
predicting virologic response to ART. Outcomes may provide a more complete picture of 
the complex factors affecting the lives of HIV-positive adults. A holistic perspective 
should be considered when providing health care or delivering interventions aimed at 
improving ART adherence and health outcomes. 
Key Words: HIV, biopsychosocial, viral load, adherence 
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INTRODUCTION 
Over 600,000 people in the United States have died from complications related to 
infection with HIV since the beginning of the epidemic (Centers for Disease Control and 
Prevention, 2013). Dramatic decreases in HIV-related  death rates since the mid-1990s 
are due  to the introduction  of highly active antiretroviral therapy (ART; Centers for 
Disease Control and Prevention Division of HIV/AIDS, 2012). Optimal adherence to 
ART can stop viral replication, rendering viral levels undetectable in both blood and 
sexual fluids and reducing risk of HIV transmission (Lima et al., 2011; Volkow, 2012). 
ART adherence  improves health outcomes by promoting ART’s effectiveness in 
suppressing viral replication and restoring immune function and is believed to be central 
to successful treatment (Bangsberg et al., 2000; Carpenter et al., 1997; Deeks et al., 1997; 
Descamps & Flandre, 2000; Katzenstein, 1997; Paterson et al., 2000). Inadequate 
treatment adherence is associated with increased mortality, viral replication, and 
increased risk of transmitting HIV  to others (Bangsberg, Perry, Charlebois, et al., 2001; 
Quinn et al., 2000). 
Several psychosocial factors, including social support, are known to have a direct 
impact on ART  adherence (Amico & Orrell, 2013; Diiorio et al., 2009; DiMatteo, 2004; 
Safren et al., 2001; Simoni, Frick, et al., 2006). Studies have shown that psychosocial 
factors may also directly improve virologic response and slow HIV disease progression 
(Ironson & Hayward, 2008); however, results are mixed. Social support may be the most 
frequently tested predictor of HIV-related health outcomes. Several studies have found 
significant positive associations between support and immunologic response or HIV 
symptoms (Ashton et al., 2005; Solano et al., 1993; Theorell et al., 1995). Other research 
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has not found a direct relationship between social support and either  biomarkers 
(Ironson, O’Cleirigh, et al., 2005) or clinical evidence of HIV disease progression (Luigi 
Solano et al., 2002; Thornton et al., 2000), although these studies show more evidence of 
effects of various psychosocial factors on clinical and immunologic disease progression 
than directly on VL. In addition, other psychosocial factors associated with HIV 
medication management such as conscientiousness and proactive coping have been found 
to positively impact ART adherence (Ironson, Balbin, et al., 2005; O’Cleirigh, Ironson, 
Weiss, & Costa, 2007). However, no prior studies have explored links between these 
psychosocial constructs and virologic response to ART, controlled for ART adherence.  
People living with HIV/AIDS (PLWH), particularly from low-income or 
disadvantaged populations, may be exposed to a range of life stressors that could inhibit 
treatment adherence (Mugavero et al., 2009; Wong et al., 2007). Stressful life events and 
trauma have not only been linked with poorer health behaviors but may also be associated 
with  lower CD4 count, higher viral load (VL), and more rapid disease progression 
(Ironson, O’Cleirigh, et al., 2005; Leserman, 2008; Leserman et al., 2007; Mugavero et 
al., 2013). Psychosocial factors such as stressful life events have also been found to affect 
health biomarkers such as CD4 count and VL via neural/endocrine mediation of stress-
related hormones such as cortisol and norepinephrine (Cole, 2008). 
Supporting Engel’s (Engel, 1977) biopsychosocial model, the field of 
psychosomatic medicine has proposed that multiple psychological and social factors may 
promote or maintain illness, suggesting that interventions should consider not only 
biological intervention (i.e. surgery and medicine) but also cognitive, behavioral, and 
emotional strategies in dealing with disease (Novack et al., 2012). The medical model, 
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accounting only for factors with a direct biological association to health outcomes, has 
reigned as the predominant paradigm of health and disease, however it is becoming more 
commonly accepted that illness and wellness are the result of an interaction between 
biological, psychological and social factors (Leigh & Reiser, 1985; Matarazzo, Weiss, 
Herd, & Miller, 1984; Sarafino, 1994). 
This holistic perspective of health and disease is important to consider, especially 
with recent efforts to increase the role of ART  in the prevention of HIV transmission. 
For example, Hermann et al. (2008) suggested in their research that the concept of ART 
adherence is dynamic, influenced by multiple biopsychosocial factors. While correlates 
of ART adherence have been studied extensively, there remains a gap in research 
examining relationships of common biopsychosocial factors and their influence on 
biomarkers such as VL. ART adherence is certainly of great importance in HIV disease 
management and prevention, but adherence alone is  useless without related  
improvement in the biomarkers that measure immune function and viremia. 
When examining the effects of psychosocial predictors on health behaviors and 
outcomes, cognitive and behavioral factors believed to moderate these relationships are 
important to consider. Many PLWH are affected by neurocognitive (NC) impairment and 
drug or alcohol abuse. Mild forms of HIV-associated NC disorders (HAND) continue to 
be observed in up to 40% of PLWH (Durvasula et al., 2009; Sacktor et al., 2002, 2007; 
Tozzi et al., 2007) and such impairment can hinder ART adherence (Hinkin et al., 2002). 
Studies have identified specific domains of functioning — such as verbal memory 
and executive functioning — associated with deficiencies in optimal ART adherence 
(Applebaum, Reilly, et al., 2009; Hinkin & Hardy, 2004; Waldrop-Valverde et al., 2006; 
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Wright et al., 2011). There is substantive evidence of the link between alcohol and 
general illicit drug use and ART non-adherence (Bryant et al., 2010; Lucas et al., 2006; 
Samet et al., 2004), but research regarding adherence and marijuana use in particular is 
mixed (Corless et al., 2009; de Jong et al., 2005; Prentiss et al., 2004; Tucker et al., 
2003). Further, research concerning marijuana use, and its potential effects upon 
virologic, immunologic and other health markers among PLWH, is limited.  
 
METHODS 
Sample 
This study sought to test a biopsychosocial model as described above, predicting 
VL, mediated by ART adherence. Internal (constant) independent variables were age, 
education and gender. External independent variables were social support, stress and 
barriers to treatment adherence, moderated by cognitive and behavioral factors (NC 
impairment, alcohol use and marijuana use).  Cross-sectional data was gathered between 
2009 and 2012 at baseline of a prospective randomized controlled trial for HIV-positive, 
adult alcohol-users. Participants were recruited from 13 community-based organizations 
in urban, low income areas of Miami, Florida. The inclusion criteria were: being ≥18 and 
≤60 years old; being HIV-positive; having consumed any alcohol in the past 3 months; 
and having a history of alcohol abuse or dependence within the past 2 years. Further 
criteria included facility in English, planning to be in the area for the next 12 months, 
understanding the informed consent, and currently not displaying overt signs of major 
psychiatric disorder including psychosis or suicidality. An additional inclusion criterion 
for this study was self-report of current prescription of ART. Of the 370 participants 
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recruited, 77% (N=273) had been prescribed ART and were eligible for this study. After 
removing 27 model-based outliers, 246 participants were evaluated. 
Measures 
Several data-gathering techniques were utilized depending on the nature and 
content of the instrument being administered. Assessment methods included: 1) 
computer-assisted personal interview (CAPI); 2) Audio computer-assisted self-interview 
(ACASI) for subjective sensitive topics; 3) paper and pen as specified for neurological 
measures and a calendar format; and 4) timeline follow-back (TLFB; Carey, Carey, 
Maisto, Gordon, & Weinhardt, 2001; Weinhardt et al., 1998) which enhances recall and 
provides a continuous three month history to assess intensity of drug and alcohol 
consumption.   
ART adherence data consisted of self-reported percentage of time ART 
medications were taken as prescribed over the course of a week, per the Community 
Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts, Telzak, & 
Chesney, 2010). The adherence score was calculated as the mean of the combined total 
amount of each medication taken during the previous week, according to the scale: “all” 
(100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%) (Mannheimer, 
Morse, John, & Andrews, 2006). The CPCRA has shown significant correlation with 
other self-report instruments (Wang et al., 2008) and has effectively predicted biologic 
outcomes (Mannheimer, Friedland, Matts, Child, & Chesney, 2002). Documentation of 
recent RNA viral load (collected by the participant’s own health care provider) was 
supplied by the participant upon entry into the study. Lab measures must have been 
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collected one month before or after the date of baseline assessment. VL was log10-
transformed for analysis. 
Tangible social support was measured using four items from the Medical 
Outcomes Study (MOS; Sherbourne & Stewart, 1991). This functional subscale of the 
19-item social support measure measures the degree to which the participant has 
instrumental help with medical or daily living needs. Each item is rated from (1) “none of 
the time” to (5) “all of the time.” A higher score indicates greater tangible support. The 
use of subscales increases sensitivity of the instrument (Sherbourne & Stewart, 1991). 
The tangible support subscale was selected because of its strength in predicting health 
outcomes and medication adherence (Gallant & Block, 1998; Gallant, 2003; Woloshin et 
al., 1993). The MOS had strong internal consistency with a Cronbach’s alpha of 0.96 for 
the full instrument and 0.89 for the tangible support subscale. All subscales have shown 
strong reliability over time (alphas > 0.91) and the four tangible support subscale items 
have high convergent validity with scale items correlating from 0.72 to 0.87 (Sherbourne 
& Stewart, 1991).  
Stress was measured with 40 items modified from the Life Experiences Survey 
(LES; Sarason, Johnson, & Siegel, 1978). The first section lists 32 potentially stressful 
events common to people in a wide variety of situations and eight additional items 
address issues more specific to this population, such as their illness and alcohol use. 
Items were scored on a Likert scale based upon the degree to which participants’ 
perceived impact of each event over the previous three months. The first 32 items were 
scored with two possible points each and the additional 8 items were scored with three 
possible points each. Higher scores indicated higher potentially stressful impact. 
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Responses to all items were summed for a total stress score. Reliability for this measure 
was strong for this sample with a Cronbach’s alpha calculated at 0.95.  
Barriers to adherence is a self-report portion of the CPCRA that offers ten 
possible reasons for missing any doses of antiretroviral medication with dichotomous 
(yes/no) responses (Mannheimer et al., 2002). Options include: “I forget to take my 
pills”; “I was away from home”; and “I am too busy.” Internal consistency of items was 
0.81. 
A battery of three neuropsychological tests was administered to derive scores in a 
range of cognitive domains including memory, information processing, and executive 
functions. The tests selected have been used in previous studies with PLWH who use 
alcohol and other drugs, and these tests have well-developed norms and high reliability 
and validity (Basso & Bornstein, 2000; Bono et al., 1996; Selnes et al., 1997; Stern et al., 
1996). The Auditory Verbal Learning Test, University of California Los Angeles/World 
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) measures immediate 
verbal memory capacity, retrieval efficiency, and learning. Fifteen words were read to the 
participant, requesting both immediate and longer-term recall. Scores for immediate 
recall, delayed recall, and percent of words retained can be derived. This study utilized 
the total of immediate recall scores for trials 1-5, with higher scores indicating greater 
functioning. This instrument demonstrated high test-retest reliability, with alpha scores 
ranging from 0.51 to 0.72 (Lezak, 2004). The Color Trails Test 2, Form A (CTT2; 
D’Elia, 1989; D’Elia, Satz, Uchiyama, & White, 1996; Lezak, 2004) is primarily a 
measure of executive functioning but also assesses attention, information processing, 
psychomotor coordination and speed. CTT-2 requires the participant to connect encircled 
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numbers 1 through 25, randomly arranged on a page, in proper order. In addition to 
measuring functions of attention and information processing, this instrument adds 
elements of mental flexibility and response inhibition. CTT-2 shows all numbers twice, 
and the participant must connect the numbers from 1 to 25, alternating between pink and 
yellow circles, disregarding the numbers in circles of the alternate color. This analysis 
uses the raw time in seconds the participant needs to complete the test, with higher scores 
indicating poorer functioning. The CTT-2  was developed for the World Health 
Organization multicenter study of HIV infection (D’Elia, Satz, Uchiyama & White, 
1996). The test is sensitive to a variety of neurological impairments and processes 
(Tombaugh, 2004) and, because it is entirely numeric and requires no language skills, it 
is considered culturally unbiased (Maj et al.,1994). Additionally, the instrument has 
shown strong agreement with other cognitive assessments among PLWH (Maj et al., 
1993; Maj et al.,1994) and has displayed good temporal stability with test-retest 
reliability between 0.85-1.00 (D’Elia et al., 1996). The Category Test Short Form-
Booklet Format (SCT; Halstead, 1947; Wetzel, 1987) measures executive function, 
assessing problem-solving ability by requiring the examinee to determine the organizing 
principle behind a series of visually presented stimuli, based on the correct or incorrect 
external feedback from the test administrator. This study uses the total raw error score 
derived, with higher scores indicating poorer functioning. Test-retest coefficients have 
varied from 0.60 to 0.96 depending upon the severity of impairment in the sample 
(Wetzel L, 1987). 
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Raw NC  scores were analyzed; unadjusted NC measures are known to provide 
better ecological validity when scores are not intended to diagnose impairment in the 
sample (Silverberg & Millis, 2009b). Scores on this battery were dichotomized. 
Participants who scored at least one standard deviation below normative means on at 
least two instruments were identified as displaying greater NC impairment (Antinori et 
al., 2007). Normative data for CTT2 and AVLT were obtained from professional manuals 
provided for the instruments (D’Elia et al., 1996; Van der Elst et al., 2005; Wetzel & 
Boll, 1987). Norms for AVLT were retrieved from The Handbook of Normative Data for 
Neuropsychological Assessment (Mitrushina et al., 2005). Comparison groups were 
assumed to be healthy, uninfected populations.  
Recent alcohol and marijuana use were assessed by TLFB (Carey et al., 2001; 
Weinhardt et al., 1998; Weinhardt, Otto-Salaj, Brondino, Norberg, & Kalichman, 2002), 
using a calendar format to enhance accurate recall and to provide a continuous history of 
drug and alcohol consumption. These two variables were measured by asking the total 
number of drinks consumed and total number of times using marijuana in the past three 
months. Up to three months recall of alcohol and other drug use has proven to provide 
reliable data (Schroder et al., 2003). An analysis of test-retest reliability yielded intraclass 
correlations ranging from 0.70 to 0.94 in a drug-using sample (Fals-Stewart et al., 2000). 
Analytic Strategy 
Descriptive statistics and skewness/kurtosis values were calculated for all of the 
variables in the model. Means and standard distributions were calculated for all 
continuous variables; percentages were provided for categorical and ordinal variables.  
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Missing data bias was evaluated by computing a dummy variable that reflected 
the presence or absence of missing data for each variable. A full information maximum 
likelihood (FIML) method was used to accommodate the missing data. Robust Maximum 
Likelihood framework accommodated issues of data distribution (Yuan & Bentler, 2000). 
A limited information approach provided approximate sample size and statistical power, 
accounting for at least 5% of variance in the outcome (Jaccard & Wan, 1996). To assess 
non-model-based outliers, leverage indices were examined for each participant based on 
his/her multivariate profile for the variables included in the model analyses. A leverage 
score four times greater than the mean leverage indicated presence of outliers. Only 
outlier cases that were uninterpretable and significantly impossible were eliminated from 
final model analysis (N=27). Model-based were defined as a participant with an absolute 
standardized DfBeta coefficient > 1.0 and none were detected based upon this criterion. 
Moderation analysis first requires the creation of product terms between each 
independent variable and each moderator, which represented the interaction effect (Aiken 
& West, 1991; Jaccard, Turrisi, & Wan, 1990). All predictor variables were centered to 
protect against multicollinearity. 
After addressing all diagnostic statistics, the final hypothesized multivariate linear 
regression model was analyzed using the Mplus software version 5.1 (Muthen & Muthen, 
2008). Non-significant product terms were sequentially dropped from the model until 
only significant ones remained. The SEM approach tested a linear moderated model such 
that Y = b0 + b1X1 + b2X2 + b3X1X2 + e. Fit indices, path values and confidence intervals 
were reported.  
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Interaction effects and mediation were analyzed separately (Fairchild & 
Mackinnon, 2009; Ryu, West, & Sousa, 2009). After confirming that all variables 
considered for a mediation model were correlated, mediation was tested in four 
traditional steps (Baron & Kenny, 1986; James & Brett, 1984; Judd & Kenny, 1981): 
Step 1 was to test associations between independent variables and the mediator. Step 2 
was to test associations between independent and dependent variables. Step 3 was to test 
the relationship between the mediator and dependent variables. Step 4 was to regress the 
independent variables on the dependent variables, controlling for the mediator to assess 
whether the association between independent and dependent variables persisted. Linear 
regression for testing mediation was conducted using SPSS version 20 (IBM, 2011). In 
addition, a Sobel Test was conducted to confirm mediation using the Sobel online 
calculator (Sobel, 1982).  
 
RESULTS 
The mean age of participants was 45 years; 66% were male, 77.3% reported their 
race as black and 13.5% reported their ethnicity as Hispanic (Table 2.1). Most (55.9%) 
participants reported at least high school graduation, but few (9%) were employed. Mean 
self-reported ART adherence over a one-week period was 93.5%, with 81.5% of 
participants reporting adherence of ≥ 95%. VL ranged from undetectable to over 900,000 
copies per mL with a mean VL of 16,246 (64,685); 28% had <50 copies/mL. NC 
impairment was observed in 34 of participants. Mean scores on all three NC measures 
were significantly lower than mean scores healthy, uninfected norms (Table 2.2).  
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Table 2.1 (1). Sociodemographic characteristics of participants and descriptive 
statistics of variables in the model (N=246) 
	  
 Mean (SD) / N (%) Skewness/ 
Kurtosis 
Age 45.24 (7.04) -0.58 / -0.05 
Gender (Male) 161 (66%) -0.68 / -1.55 
Hispanic ethnicity (Yes) 33 (13.5%) - 
Race  - 
Black 187 (77.3%) - 
White 36 (14.9%) - 
Years education  0.44/ -0.18 
<8th grade 19 (7.8%) - 
Some high school 89 (36.3%) - 
High school graduate 70 (28.6%) - 
Some college/tech 53 (21.6%) - 
College degree 11 (4.5%) - 
Graduate training 3 (1.2%) - 
Employed (Yes) 22 (8.9%) - 
ART adherence (percent)1 93.5 (19.96) -3.59/ 12.83 
VL  16,948 (64,685) 7.06 / 58.27 
VL (undetectable) 69 (28%) - 
Social Support (MOS) 13.30 (4.85) -0.23 / -0.74 
Stress (LES) 47.85 (34.46) -0.33 / -0.88 
Barriers to adherence (zero) 165 (89.2%) 3.37 / 11.30 
Alcohol (# drinks/90 days)  173 (261.18) 3.18/ 12.02 
Marijuana (# times using/90 days) 19.17 (34.77) 1.62 / 1.11 
NC impairment (Yes) 84 (34.1%) 0.54  -1.71 
 
1 Median adherence = 100% 
 
 
Table 2.2 (2). Neurocognitive scores for participants and healthy norms (N=246) 
	  
NC Instrument Raw Score (SD) Norms 
CTT2  129.14 (53.72)* 96.35 (29.57) 
SCT  36.65 (15.58)* 27.35 (12.1) 
AVLT  43.13 (9.44)* 51.1 (8.6) 
 
*significant at p<0.001 
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The sample size (246) accounted  for at least 5% of unique variance in the 
outcome, modeling for multiple regression analysis with 11 predictors, squared multiple 
correlation of 0.10 (the lowest observed in the modeling) and a 0.05 alpha level, yielding  
a satisfactory power coefficient of 0.98. The mean leverage score across participants was 
0.139, and 27 outliers were identified based upon the leverage score criterion described 
above. None of the correlations to assess missing data bias were statistically significant, 
indicating that data were missing at random. After examining data for distribution issues, 
outliers and patterns of missing data, the final moderated model was tested (Figure 2.1), 
presenting both significant and non-significant path coefficients of the final model with 
non-significant product terms removed. The straight lines with arrows from observed 
variables represent presumed pathways of association and the values along the pathways 
are unstandardized path coefficients—expressed in terms of actual scores. All exogenous 
variables were assumed to be correlated. Unstandardized path coefficients, standard 
errors and 95% confidence intervals are listed in Table 2.3. The final model was just 
identified and no fit indices are reported. 
The final model explained 31% of variance in ART adherence and 18% of 
variance in log10 VL. When examining associations between predictors and outcomes, 
two significant paths were identified. Each increase in number of barriers to adherence 
predicted a 10.06% decrease in adherence to ART and also predicted a 0.42 unit increase 
in log10 VL. No interaction effects were identified.   
A modest association between marijuana use and ART adherence was observed 
and approached significance (β=0.15, p=0.057); however the variable “barriers to 
medication adherence” was the only independent variable significantly associated with 
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both ART adherence and VL in the SEM, so this was the only variable considered for 
further testing in a mediated relationship. Barriers, ART adherence and VL were 
significantly correlated (Table 2.4).  
Linear regression results for mediation testing are reported in Table 2.5. Step 1: 
“Barriers” was significantly negatively associated with adherence (β=-9.47; p < 0.001). 
Step 2: “Barriers” was significantly associated with higher VL (β= 0.30; p=0.002). Step 
3: Adherence was associated with lower VL (β=-0.02; p=0.05). Step 4: “Barriers” ceased 
to be associated with VL when controlling for adherence (β=0.20; p=0.09). This suggests 
that mediation was not full, as confirmed by the Sobel Test (β=0.99, p=0.32) but much of 
the effect of “barriers to adherence” on VL was apparently due to their effect on ART 
adherence.  
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Figure 2.2 (2). Regression paths among measured variables in the structural 
equation model among HIV-positive alcohol abusers (N=246) 
 
*P<0.05 
Regression coefficients (represented as one-way arrows) are unstandardized.  
 
 
Table 2.3 (3). Unstandardized path coefficients, standard errors, 95% confidence intervals 
and p-values (N=246) 
 
  Coefficient SE 95% CI P 
Support Adherence 0.56 0.41 -0.49, 1.60 0.17 
VL 0.02 0.13 -0.05, 0.08 0.54 
Stress Adherence -0.002 0.05 -0.13, 0.13 0.97 
VL -0.002 0.004 -0.01, 0.01 0.57 
Barriers to 
Adherence 
Adherence -10.06 1.72 -14.49, -5.63 <0.001 
VL 0.42 0.13 0.08, 0.75 0.001 
NC1Impairment Adherence 2.09 2.29 -3.81, 7.99 0.36 
VL -0.25 0.26 -0.91, 0.41 0.33 
Marijuana Adherence 0.15 0.08 -0.05, 0.34 0.06 
VL 0.01 0.01 -0.01, 0.02 0.14 
Alcohol Adherence 0.02 0.07 -0.18, 0.21 0.84 
VL 0.00 0.01 -0.02, 0.02 0.95 
Age Adherence 0.19 0.19 -0.30, 0.69 0.31 
VL 0.02 0.02 -0.04, 0.07 0.44 
Education Adherence 1.51 1.52 -2.40, 5.42 0.32 
VL -0.15 0.11 -0.44, 0.13 0.16 
Gender Adherence 3.63 2.91 -3.86, 11.11 0.21 
VL 0.20 0.29 -0.45, 0.85 0.49 
1 NC Neurocognitive 
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Table 2.4 (4). Correlation matrix for all variables in the model (N=246) 
 1 2 3 4 5 6 7 8 9 10 
1.Adhere 1.00          
2. VL -0.26* 1.00         
3.Support  0.15 -0.01 1.00        
4. Stress 0.04 -0.06 0.02 1.00       
5. Barriers -0.50* 0.36* -0.07 0.02 1.00      
6. NC.Impairment 0.06 -0.08 0.00 0.14 -0.01 1.00     
7. Alcohol 0.01 0.01 -0.07 -0.06 0.00 0.08 1.00    
8. Marijuana 0.11 0.10 -0.04 -0.04 0.04 0.00 -0.04 1.00   
9. Age 0.08 0.01 -0.16 -0.07 0.06 0.14 0.02 0.18 1.00  
10. Gender 0.06 0.08 -0.13 -0.13 0.15 0.03 0.08 0.10 -0.04 1.00 
11. Education 0.01 -0.06 -0.03 -0.17 -0.01 -0.11 -0.04 -0.02 0.00 0.06 
*Significant at p<0.01 
 
Table 2.5 (5). Linear regressions, test for mediation (N=246) 
 Unstd. β SE 95% CI P R2 
Barriers1 =>Adherence -9.47 1.03 -11.50, -7.43 0.00 0.35 
Barriers =>VL 0.30 0.10 0.11, 0.49 0.002 0.08 
ART Adherence=>VL -0.02 0.01 -0.03, -0.003 0.02 0.05 
Barriers (control for Adherence) =>VL 0.21 0.01 -0.03, 0.01 0.09 0.1 
Adherence (control for Barriers) =>VL -0.01 0.01 -0.03, 0.009 0.29 0.1 
1.Barriers to ART Adherence 
Sobel p=0.32 
 
 
DISCUSSION 
Results from this study provide modest support for a biopsychosocial approach to 
understanding the HIV-related health outcome studied, specifically, virologic 
suppression. The biopsychosocial model suggests that psychosocial, cognitive and 
behavioral factors may directly influence a biomedical outcome (Engel, 1977). This 
model has been successfully applied to disease processes and causes (Alonso, 2004; 
Matarazzo & Leckliter, 1988) but less successfully applied to health outcomes. When 
used to examine health outcomes, the biopsychoscial model is most often applied to 
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disease symptoms such as pain (Jones et al., 2002; McLean, Clauw, Abelson, & 
Liberzon, 2005), and biomarkers of chronic disease (blood pressure, blood sugar) or 
gastrointestinal illnesses (Drossman, 1998). In HIV infection, a considerable body of 
evidence suggests that stressors may adversely affect biomarkers of disease progression, 
particularly CD4 count and mortality (Ironson & Hayward, 2008). Unlike VL, these 
health outcomes have been clearly linked to the stress-response system, also termed the 
hypothalamo-pituitary-adrenal (HPA) axis. In a comprehensive review of empirical 
studies, Cole (2008) suggested that sympathetic nervous system and HPA axis mediation 
may exist between psychosocial factors and HIV pathogenesis, that is, how HIV causes 
illness, particularly immunosuppression. Less support exists for a direct link between 
HPA axis function and VL. 
In this study, the only psychosocial variable found to be significantly associated 
with VL was barriers to adherence to ART. Although it is a measure of perceived 
barriers, this construct may be a proxy for ART adherence itself. Hence, this study 
provides only modest support for the application of a biopsychosocial model predicting 
VL among PLWH. The relationship between number of barriers and actual adherence 
rates has been observed in other studies  (Catz et al., 2000). However, no such studies 
were identified that include VL as a health outcome.  The present study suggests, 
however, that ART adherence does not mediate fully the relationship between perceived 
barriers and VL. Were adherence to mediate fully the relationship between barriers and 
VL, no direct influence of the psychosocial predictor on the biomedical outcome could be 
supported.  
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Identifying direct links between psychosocial factors and HIV biomarkers has 
proved challenging. Thornton et al., (2000) conducted a longitudinal analysis of CD4 
count and time to AIDS diagnosis, predicted by stressful life events and social support. 
Neither was found to be significantly associated with these outcomes. In addition, a meta-
analysis conducted by Zorilla, et al. similarly found no psychosocial predictors of HIV 
progression (Zorrilla, McKay, Luborsky, & Schmidt, 1996). Finally, Solano et al., (1993) 
reported several psychosocial variables associated with disease progression in  PLWH 
with poorer immune functioning, although  these were not strong predictors for those 
with higher CD4 counts. 
 Multiple studies have revealed effects of stress or social support on HIV 
biomarkers or other indicators of disease progression (Ashton et al., 2005; Ironson & 
Hayward, 2008; Ironson, O’Cleirigh, et al., 2005; Leserman, 2008; Mugavero et al., 
2013; Theorell et al., 1995).  None of the studies describing such effects after the 
introduction of ART investigated the possibility of ART adherence acting as a mediating 
variable. As reported for a biopsychosocial model exploring the effects of stress, stability 
and treatment adherence on insulin-dependent diabetes (Peyrot, Mcmurry, & Kruger, 
2013), medication adherence (ART adherence in the case of this study) is essential in 
chronic disease management to achieve optimal health outcomes.  
Alcohol abuse has been shown to result in deleterious physical outcomes 
including poor adherence to health care recommendations, particularly for following a 
medication regimen (Bryant, 2006; Cook et al., 2001; Samet et al., 2004), however this 
study did not identify such associations. On the contrary, a modest positive association 
between marijuana use and ART adherence approached statistical significance in this 
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study. Although research has found marijuana use to decrease ART adherence (Tucker et 
al., 2003), some studies suggest that marijuana use may serve to reduce symptoms and 
improve ART adherence among PLWH (de Jong et al., 2005). It is possible that different 
degrees of use or dependence may play a role in whether this drug serves to improve or 
hinder ART adherence (Bonn-Miller, Oser, Bucossi, & Trafton, 2012). 
Certain limitations of this study should be noted when interpreting results. First, 
participants were recruited from clinical sites, reducing generalizability to non-clinical 
samples. Also, about one-third of the sample was in residential drug or alcohol treatment 
at the time data were collected, and reporting bias may exist particularly for responses to 
questions about drug and alcohol use. The fact that many participants were engaged in 
care may also account for the unusually high adherence rates reported in this sample. 
High adherence rates may also be explained by the use of self-report measurement which 
has been found to provide inflated values (Cramer, Mattson, Prevey, Scheyer, & 
Ouellette, 2013; Waterhouse, 1993). Finally, findings reported are based on a cross-
sectional analysis. In examining mediation, Maxwell and Cole (2007) note that estimates 
using cross-sectional data may be biased (as compared with longitudinal data) because of 
the failure to allow for autoregressive effects of the mediator and outcome variables. 
Baron and Kenny (1986), Holland (2013), and MacKinnon (2007) caution that without a 
randomized experiment one cannot rule out possible alternative explanations accounting 
for significant associations identified. 
Findings from this study suggest that viral suppression among PLWH is largely a 
product of ART adherence, with a modest direct effect of psychosocial factors. Since 
ART adherence remains the primary predictor of virologic suppression and improved 
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health outcomes among PLWH, fostering adequate medication management must remain 
a priority for the HIV care community. However, ART adherence rates are subject to 
fluctuations based upon stress, social support, NC impairment and drug and alcohol use. 
Thus, maintaining a holistic perspective of health care and regard for the myriad 
psychosocial factors in the lives of PLWH can improve health outcomes. It is important 
to assess broader, more ecological models for determining health outcomes such as viral 
load when a biomedical approach alone has failed to eradicate HIV progression and 
transmission.  Findings from this study may help shed light on psychosocial factors 
associated with HIV-related health and illness that are responsive to intervention. 
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CHAPTER V 
TRANSITION TO MANUSCRIPT 3 
Following is the final manuscript of this dissertation. This study evaluates the 
effectiveness of an evidence-based intervention on improving antiretroviral treatment 
adherence, increasing service utilization and reducing viral load among people living 
with HIV. Although Manuscripts 1 and 2 also examined data gathered in the same parent 
study, this study is prospective, utilizing data before and up to six months after the 
delivery of the intervention. Hence, the study population size is smaller than those of the 
former studies because of attrition: of the 337 participants assigned to cohorts at baseline, 
211 were available to complete assessments at 6 months post-intervention. 
Outcomes from the prior two cross-sectional manuscripts helped contribute to the 
conceptualization of this set of analyses. For example, Manuscript 1 provided 
information about the overall neurocognitive functioning for this sample, which helped 
explain how this intervention’s cognitive remediation strategies may have aided in 
positive health behavior outcomes. In Manuscript 2 no association was found between 
tangible social support and ART adherence, so in this study the general social support 
scale was utilized. Although “barriers to adherence” was a significant predictor of 
adherence in Aim 2 of this dissertation, it was not central to the theoretical model for the 
following study and was therefore dropped. 
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MANUSCRIPT 3: EFFECTIVENESS OF AN EVIDENCE-BASED 
INTERVENTION IN IMPROVING TREATMENT ADHERENCE, SERVICE 
UTILIZATION AND VIRAL LOAD AMONG HIV-SEROPOSITIVE ADULT 
ALCOHOL USERS 
ABSTRACT 
Background: Up to 95% adherence to antiretroviral therapy (ART) may be necessary to 
sustain viral suppression and reduce risk of HIV transmission; however, achieving high 
levels of adherence may be challenging for people who abuse alcohol or suffer from 
neurocognitive impairment. This study evaluated whether a manual-guided intervention 
significantly improved ART adherence, service utilization and VL among HIV-positive 
adults with a history of alcohol abuse. 
Methods: A total of 243 HIV-seropositive adults, recruited from community based 
organizations in South Florida were randomized to the Holistic Health Recovery Program 
(HHRP-A) or a comparison condition. Both groups attended eight sessions and provided 
self-reported data on outcomes, including adherence, service utilization, and viral load 
(VL), and on processes, including social support and stress. Data were collected at 
baseline, immediately post-intervention, 3-month, and 6-month follow-up time points. 
Results: Participants were ≥18 and ≤60 ( =45.7 years old), 74% male, and 78% black. 
Participants randomized to the HHRP-A condition were significantly more likely to 
report adequate ART adherence and to report an undetectable VL at 6 months post-
intervention. An effect was also observed on social support, with participants in the 
HHRP-A condition showing significantly greater improvement than the comparison 
group. 
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Discussion: Findings suggest that providing comprehensive health promotion 
interventions, particularly those incorporating cognitive remediation strategies, could 
greatly improve self-reported health outcomes for HIV-seropositive substance users.  
Key Words: HIV, alcohol, adherence, intervention, addiction 
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INTRODUCTION 
Since the mid-1990s, antiretroviral therapy (ART) has successfully extended the 
lives of people living with HIV/AIDS (PLWH; Centers for Disease Control and 
Prevention Division of HIV/AIDS, 2012a, 2012b; Palella et al., 1998). Thus, the goal of 
HIV care has shifted toward achieving long-term optimal health outcomes through 
consistent treatment. Adequate adherence to ART improves health outcomes and is 
critical for successful disease management; conversely, inadequate treatment adherence is 
associated with increased morbidity and mortality, viral resistance, limited future 
treatment options and increased risk of HIV transmission to others (Bangsberg, Perry, & 
Charlebois, 2001; Bangsberg et al., 2000; Carpenter et al., 1997; Deeks, Smith, Holodniy, 
& Kahn, 1997; Paterson et al., 2000; Volkow & Montaner, 2010). As much as 95% 
adherence may be necessary to achieve positive clinical outcomes. However, achieving 
the level of adherence necessary to suppress viral replication can be challenging, with 
recent studies reporting that anywhere between 18% and 73% of PLWH are non-adherent 
to antiretroviral therapy (Bangsberg, Moss, & Deeks, 2004; Catz, Kelly, Bogart, 
Benotsch, & Mcauliffe, 2000; Lucas, 2005; Paterson et al., 2000; Tesoriero et al., 2003).  
These adherence levels  may be even lower for PLWH experiencing  alcohol 
abuse or neurocognitive impairment [NCI] (Baum et al., 2010; Braithwaite & Bryant, 
2010; Bryant, 2006; Cook et al., 2001; Hinkin, Castellon, & Durvasula, 2002; Rothlind et 
al., 2008), both of which are commonly comorbid with HIV. Alcohol abuse has been 
reported by up to 53% of adults with HIV (Galvan et al., 2002; Heaton et al., 2010) and 
NCI ranging from asymptomatic neurocognitive impairment (ANI) to HIV-associated 
dementia (HAD) has been observed in about 37% of adult PLWH (Sacktor, 2002). Heavy 
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alcohol use and NCI may have a negative synergistic effect on self-reported medication 
adherence and service utilization rates (Bass et al., 2012; Marx, Malka, Ravishankar, & 
Schwartz, 2011; Rothlind et al., 2005). Improving utilization of both HIV and substance 
abuse services is central to increasing treatment adherence and optimizing health 
outcomes for PLWH (Mugavero et al., 2009, 2013; White House Office of National 
AIDS Policy, 2010). Through adequate and consistent care, patients are better able to 
receive the support necessary to achieve adequate treatment adherence, sustain optimal 
health outcomes, and, ultimately, help to reduce the incidence of HIV. Hence, there 
remains a pressing need to continue developing, adapting, and testing evidence-based 
interventions aimed at improving service and care utilization and improving health 
behaviors such as ART adherence. 
One theoretical framework that has effectively predicted HIV-related health 
behaviors in diverse samples is the Information-Motivation-Behavioral Skills (IMB) 
model (Fisher & Fisher, 1992). Several empirical tests of this model have established the 
strength of its three major constructs in predicting ART adherence and service utilization 
(Amico et al., 2005; Margolin et al., 2003; Smith, Fisher, Cunningham, & Amico, 2012; 
Starace et al., 2006). An adaptation of the IMB model proposed by Fisher et al. (2008) 
posits that ART treatment-related information and motivation to be adherent will operate 
through necessary behavioral skills to influence adherence-related health behaviors 
(Fisher, Amico, Fisher, & Harman, 2008). To benefit from an IMB-guided intervention, 
participants are expected to possess the cognitive capacity to process and translate 
intentions into health behaviors. These capacities may be diminished among HIV-
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seropositive adults with a history of alcohol abuse (e.g., Farinpour et al., 2000), thus 
impeding their abilities to benefit from a therapeutic intervention. 
This study evaluated the effectiveness of an IMB-based, manual-guided 
intervention on improving outcomes of viral load (VL), ART adherence and service 
utilization among PLWH with a history of alcohol abuse. While this intervention was 
geared primarily toward reducing sex and drug/alcohol risk behaviors, service utilization, 
ART adherence and virologic response were secondary aims of the intervention. Process 
variables associated with the development of these outcomes were derived from the 
Fisher et al. (2008) IMB adherence model and the buffering model of social support 
(Cohen & McKay, 1985). Prior research applying these models have found that both 
stress reduction and increasing social support are strongly predictive of ART adherence 
and service utilization outcomes (Catz et al., 2000; DiMatteo, 2004; Gonzalez et al., 
2004; Mugavero et al., 2009; Simoni et al., 2002; Simoni, Frick, et al., 2006; Wong et al., 
2007).  
Using recommended methodologies for testing manual-guided interventions 
(Hirokazu, Wilson, Peterson, & Shinn, 2005), a randomized	  clinical trial was conducted 
to determine whether a manual-guided risk reduction intervention produced lower VL 
and greater antiretroviral treatment adherence and service utilization outcomes over and 
above a standard-of-care, health promotion comparison group. The delivery of a group 
intervention that included cognitive remediation strategies and addressed this 
population’s unique needs was expected to facilitate learning and retention of risk 
reduction behavioral skills central to achieving these outcomes. In addition, the study 
sought to assess whether a reduction of stress and an increase in social support was 
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achieved and if these factors provided any additional contribution to achieving the 
intended outcomes.  
 
METHODS 
Participants 
A total of 370 HIV-seropositive, alcohol-using adults were recruited from 
community-based organizations (CBOs) in Miami, Florida between January 2009 and 
November 2012. A slower recruitment period was planned to help prevent against 
treatment group contamination and group assignment bias. The inclusion criteria were: 
being 18-60 years old;  documented HIV infection; having consumed any alcohol in the 
past 3 months; having a history of alcohol abuse or dependence within the past 2 years; 
displaying facility in English; ability to understand the informed consent; ability to be 
located for follow-up over the course of a year; willingness to be randomized to a 
treatment or control group; and currently not showing overt signs of major psychiatric 
disorder including psychosis or suicidality. An additional inclusion criterion for this study 
was self-report of current prescription of ART. 
After participants completed the baseline assessment, they were entered into the 
study in cohorts of eight participants of the same gender. Cohorts were assigned to 
receive either the experimental or control condition according to a computer-generated 
random sequence. The random sequencing was expected to control for bias in subject 
assignments across conditions.	  Assessment methods included: CAPI (computer assisted 
personal interview); ACASI (audio computer assisted self-interview) for subjective 
sensitive topics; and paper and pen as specified for neurological measures. Data were 
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collected at baseline (T1), immediately post-intervention (T2), 3 month follow-up (T3), 
and 6 month follow-up (T4) for all measures; however, no adherence or stress data were 
collected at T2.  
The research protocol was approved by the Institutional Review Board of Florida 
International University, and all participants provided signed informed consent prior to 
participating in the study. Participants were offered decremental monetary compensation: 
$50 gift cards to local stores upon completing the first assessment; $25 gift card upon 
completing post-assessments; $15 cash or gift card for attendance at each group session; 
and $5 cash for transportation. 
Outcome measures 
ART adherence was defined as the self-reported percentage of time ART 
medications were taken as prescribed over the course of a week. The Community 
Programs for Clinical Research on AIDS (Mannheimer, Matts, Telzak, & Chesney, 2010) 
assesses whether the individual has accurately taken all doses of the medications. For 
each antiretroviral medication taken, participants rated their adherence according to the 
scale: “all” (100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%); the 
mean adherence for all medications was calculated (Mannheimer, Morse, John, & 
Andrews, 2006). Perfect adherence was defined as greater than 95%. While definitions of 
adherence have varied greatly in the literature, this cutoff was set to compare with the 
level established by Margolin (2003).  Self-reported adherence was significantly 
correlated with serum VL at baseline (rs=-0.33, p=0.02). 
Service utilization was assessed using a section of the Treatment Services Review 
(TSR) portion of the CSAT-GPRA Client Outcome Measures for Discretionary Programs 
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(McLellan et al., 1992; Mclellan et al., 1989). The TSR is an instrument designed to 
collect intake data at addictions treatment facilities. The section of the assessment used in 
this study asked the participant “Are you currently or ever received any of the following 
Treatment Service?” The 52 services listed are relevant to HIV-positive substance 
abusers, including screening, recovery, case management, medical, after care, education, 
and peer-based recovery support services. Three additional items from the CPCRA were 
included: 1) “Do you receive any financial assistance to buy medications (such as ADAP, 
Ryan White or other government or charitable agency?”); 2)	  “Is there a clinic, health 
center, doctor's office, or some other place that you usually go if you are sick or need 
medical care?”; and 3) “Do you have health insurance?” The TSR has high test-retest 
reliability, concurrent validity in differentiating between levels of care (McLellan et al., 
1992), and a Cronbach’s alpha of 0.93 at baseline of this study.  
Viral load (VL) was  a self-report measure using a single question from the 
CPCRA (Mannheimer, Friedland, Matts, Child, & Chesney, 2002; McLellan et al., 1992). 
Participants were asked to “Indicate your viral load the last time it was measured” with 
available responses: 1) undetectable, 2) 50-500, 3) 501-5,000, 4) 5,001-10,000, 5) 
10,001-30,000, 6) 30,001 or more, 7) don’t know. Self-reported VL measures were 
significantly correlated with blood measures at baseline (rs=-0.21, p=0.03). Percent 
reporting an undetectable VL was reported. 
Process measures 
Social support was measured using all 19 items from the Medical Outcomes 
Study (MOS; Sherbourne & Stewart, 1991). Questions concerned medical condition-
related quality of life and comprised of four functional support scales: 
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emotional/informational, tangible, affectionate, and positive social interaction. Each item 
is rated from (1) “all of the time” to (5) “none of the time.” The overall social support 
index (total score) was used, with a higher score indicating more support. The MOS was 
developed for patients involved in a 2-year study investigating chronic conditions. All 
subscales have shown strong reliability over time (alphas > 0.91). For this study sample 
the Cronbach’s alpha was 0.96.  
Stress was measured with 40 items modified from the Life Experiences Survey 
(Sarason, Johnson, & Siegel, 1978) and the Perceived Stress Scale (Cohen et al., 1983) 
developed by the Semel Institute-Neuropsychiatric Institute (NPI) of the University of 
California, Los Angeles (available at http://chipts.ucla.edu/wp-
content/uploads/downloads/2012/02/Life-Events.pdf). The first section is a list of 32 
events common to people in a wide variety of situations such as divorce, moving, and 
loss. If a participant indicated that an event occurred in the past three months, s/he rated 
it: (1) “very bad,” (2) “somewhat bad,” (3) “somewhat good,” and (4) “very good.” Items 
rated (1) or (2) were reverse scored and summed for a negative impact score. Items rated 
3 or 4 were not counted (Sarason, et al., 1978). Eight additional items listed issues more 
specific to PLWH, such as their illness and alcohol use and rated on the degree to which 
each issue bothered them from (1) “not at all” to (5) “extremely.”   Items scored (3), (4), 
or (5) were recoded from 1-3 respectively and added to the negative impact score for a 
total of 88 possible points. Reliability for this measure was strong for this group with a 
Cronbach’s alpha calculated at 0.95.  
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Treatment conditions 
Experimental Condition (n=127, 52.3%) 
The evidence-based intervention evaluated was an adapted version of the Holistic Health 
Recovery Program (HHRP-A) which has been translated to manual format for in detail 
uniform implementation (Margolin et al., 2003), and disseminated by the CDC’s 
Diffusion of Effective Behavioral Intervention (DEBI) program 
(www.effectiveinterventions.org) program. Some HHRP-A core elements include 
teaching: decision-making and problem solving skills using cognitive remediation 
strategies; goal-setting skills, including developing action plans; skills to manage stress, 
including relaxation exercises and understanding what aspects of the stressful situation 
can, and cannot, be controlled; skills to improve health, healthcare participation, and 
adherence to medical treatments; skills to increase clients' access to their own self-
defined spiritual beliefs, in order to increase motivation to engage in harm reduction 
behaviors; and skills to increase awareness of how different senses of self can affect self-
efficacy and hopelessness. In addition, the group-based intervention is designed to 
promote interaction between participants so that they build positive social support 
networks with peers.  Diffusing risk-reduction messages in peer-based social support 
networks may help to sustain benefits of HIV interventions (Latkin and Knowlton, 2006). 
Per the design of the evidence-based HHRP, group facilitators were staff similar 
in profile to those of the CBO recruitment sites in that they had a high school-to-bachelor 
level education and were familiar with urban Miami-Dade County. Participants attended 
eight 2-hour sessions scheduled 1 to 2 times per week over consecutive weeks conducted 
from February 2009 through December, 2012. The HHRP therapy manual 
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(http://info.med.yale.edu/psych/3s/HHRP_manual.html) was highly structured, and 
involves both didactic presentation of material as well as experiential exercises. Content 
matter was comprehensive in order to address the medical, emotional, and spiritual needs 
of individuals living with HIV. Topics addressed by HHRP-A included: stress reduction, 
harm reduction skills training; relapse prevention; improving emotional, social, and 
spiritual health, including coping with stigma and grief; increasing medication adherence; 
improving participation in medical care; and making healthy lifestyle choices, including 
reducing HIV sexual transmission risk behavior. Each session was co-facilitated by two 
counselors using a nonjudgmental, motivational enhancing therapeutic style (Miller & 
Rollnick, 1991).  
Cognitive remediation strategies (Miller, 1993) were incorporated because of the 
potential for NCI in this population. These strategies included: varied presentation 
modalities; repetition and review; behavioral games; memory books; reduction of 
distraction and fatigue; emphasis on structure and consistency; ongoing assessment of 
new learning and retention, with immediate provision of feedback, and stress 
management. 
Comparison Condition (n=116, 47.7%) 
The randomized design compared the experimental treatment to a Health 
Promotion Comparison (HPC) condition. The HPC was not designed to provide the IMB-
driven techniques of HHRP-A. This condition was meant to be educational and didactic, 
addressing common health problems, personal hygiene, nutrition, physical fitness, 
smoking avoidance/cessation, and healthy living. HPC did not incorporate behavioral 
skills training or motivational enhancement techniques and did not promote interaction or 
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social support network development. HPC matched HHRP-A in total administration time 
and format (eight 2-hour sessions); however this modality was condensed and delivered 
over a period of only two days in order to reduce the risk of possible inflated effects in 
comparison group outcomes as a result of longer-term group involvement and attention.   
As in HHRP-A, HPC was guided by a written manual, implemented, and held 
under the same conditions so as to produce equivalent facilitator attention and expectancy 
of benefit and to control for effects that could be attributed to nonspecific features of 
HHRP-A.  
A standard care HIV education component was included in the HPC as it was 
deemed ethically responsible to include some HIV education in a comparison condition, 
given the high-risk nature of this population. Thus, one session of the HPC condition 
delivered a standard care level of HIV risk reduction, simulating what may be considered 
a “usual” care level that participants might expect to receive in a typical CBO program. 
To prevent cross-group contamination, each cohort group was staggered in time and 
space (sessions were scheduled to take place at alternating locations). Since participants 
came from different locations, there was a reduced possibility of cohorts interacting and 
thus discussing their respective experiences on site. Finally, study coordinators estimated 
that any inadvertent exchange of information between HHRP-A and HPC members 
would be more likely to reduce the differences between the two groups than bias the 
results to inflate Type 1 errors. 
Analysis 
Analyses were conducted with SPSS version 20 (IBM, 2011). Continuous 
measures were service utilization, stress and social support. Data were assessed for 
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random missingness (MCAR) using Little’s Missing Completely At Random Test 
(Allison, 2001; Little, 1988) and continuous quantitative missing values were imputed 
using the expectation maximization algorithm (Dempster et al., 1977). The three 
continuous variables were square root transformed for analysis due to moderate non-
normal distribution (Tabachnick and Fidell, 2007; Howell, 2007). Change over time on 
continuous measures was analyzed using 2 X 3 or 4 repeated measures analyses of 
variance (ANOVAs) to account for treatment condition and time variables. Where change 
over time in any continuous variable was detected, effect sizes (partial η2) were reported 
if statistically significant (Richardson, 2011).  
For the dichotomous variables, VL (detectable or undetectable) and adherence 
(>95% versus lower), changes between each time point were analyzed using McNemar-
Bowker tests (Bowker, 1948). Dichotomous variables were also cross-tabulated by 
treatment group at each time point using chi-square analyses. Rate (prevalence) ratios 
(RRs) and 95% confidence intervals (CIs) are presented. Significance criteria were 
Bonferroni-adjusted for number of analyses. Missing categorical data were not imputed.  
Controlling for VL at baseline, Spearman’s rank correlation between baseline 
adherence and VL at T4 was calculated as a partial test of veracity and accuracy of the 
self-reported adherence measure (Margolin et al., 2003), implicitly assuming absence of 
significant resistance to the antiretrovirals prescribed. Additional Spearman’s rho and 
Pearson correlations (as appropriate) were calculated between process and outcome 
variables.  
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RESULTS 
Socio-demographics  
All consecutively recruited PLWH were screened for eligibility; 337 of the 
eligible participants met all requirements for randomization and the 243 who reported 
receiving ART at all time points were included in this study. Table 1 presents 
sociodemographic, HIV, and NC descriptive characteristics of the participants at baseline 
prior to randomization. The final sample for the intervention was 70.8% male and had a 
mean age of 45 (SD=6.9) years. Nearly 80% identified as African American and 12.2% 
as White. Fourteen percent considered themselves to be of Hispanic ethnicity. A total of 
55% had at least a high school diploma and 9% were employed. At entry into the study, 
participants provided recent (within one month from intake) lab tests of CD4 count and 
VL; means were 440 and 11,588 copies/ml, respectively with 26% showing an 
undetectable viral load. A large proportion of participants displayed a degree of NCI; 
38.7% scored at least one standard deviation below the mean for normative samples on at 
least two neuropsychological tests sensitive to a range of cognitive capacities (Antinori et 
al., 2007).  
	  
Table 3.1 (1).  Descriptive characteristics of all randomized sample at baseline  
 HHRP-A 
N=127 
Mean (SD) 
N (%) 
HPC 
N=116 
Mean (SD) 
N (%) 
TOTAL 
N=243  
Mean (SD) 
N(%) 
Age 45.71 (6.3) 44.68 (7.5) 45.22 (6.90) 
Gender    
Male 93 (74%) 77 (67%) 170 (71%) 
Female 32 (26%) 38 (33%) 70 (29%) 
Education    
<8th Grade 9 (7%) 10 (9%) 19 (8%) 
Some HS, not graduate a 45 (37%)  40 (36%) 85 (37%) 
HS graduate or GED 32 (26%) 34 (31%) 66 (29%) 
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Some college 26 (22%) 19 (17%) 45 (19%) 
College degree 7 (5.8%) 6 (6%) 13 (6%) 
Any graduate training 2 (2%) 1 (1%) 3 (1%) 
Hispanic Ethnicity 16 (13%) 17 (16%) 33 (14%) 
Race    
Black 92 (78%) 87 (80%) 179 (79.6%) 
White 17 (15%) 11 (10%) 28 (12.4%) 
Employed (Yes) 9 (7%) 12 (11%) 21 (9%) 
Years living with HIV 12.89 (6.92) 13.55 (7.53) 13.20 (7.23) 
CD4 count (copies/ml) 449 (218) 430 (240) 440 (228) 
Plasma Viral Load (copies/ml)1 10,870 (22,159) 13,411 (73,158) 12,083 (52,921) 
Viral Load (<50 copies/mL) 25 (20%) 38 (33%) 63 (26%) 
Neurocognitive functioning (raw scores)    
Auditory Verbal Learning Test  43.78 (9.04) 43.46 (9.75) 43.62 (9.35) 
Short Category Test (trials 1-5) 37.23 (15.92) 39.95 (12.93) 38.53 (14.60) 
Color Trails Test 2 119.63 (50.40) 114.25 (55.04) 117.06 (52.62) 
 
1Median VL=2,460 for all participants	  
 
Receipt of intended level of treatment and retention 
Group participants agreed to be videotaped and rated for counselor competence 
and observance of the implementation manual (Carroll, Kadden, Donovan, Zweben, & 
Rounsaville, 1994). There were no significant differences in adherence, service 
utilization, or VL measures by treatment group assignment at baseline. Of the 243 
randomized participants, 87% completed at least 6 out of 8 intervention sessions; 63% 
were available at the 6-month follow up to complete the survey instruments (Figure 3.1) 
and those completing 6 month assessments did not differ significantly by group 
assignment However, session completion varied significantly by study assignment, with 
84/127 (66.1%) of eligible participants assigned to the treatment condition completing >6 
sessions, versus 104/116 (89.7%) of comparison group participants (t=4.95; p<0.001).  
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Figure 3.1 (1). Number of participants enrolled at each time point (N=243) 
	  
*Number of sessions attended was significantly different between groups (t=4.95, p<0.001) 
  Proportion who completed all sessions was significantly different between groups (χ2=46.70, p<0.001) 
	  
Outcomes 
Of all participants who reported being on ART throughout the study (N=243), the 
following proportions reported better than 95% adherence: 83% at baseline, 89.3% at T3 
and 86.6% at T4 (Table 3.2). Changes in reported adherence across time points were not 
statistically significant. Chi square analyses (Table 3.3) showed a significant difference 
(RR=1.55; 95% CI: 1.09, 2.18; p=0.049) between treatment groups in the proportions of 
140 
	  
participants reporting >95% adherence at T4 (HPC=80.6% versus HHRP-A=90.3%). No 
differences in adherence or VL between conditions observed at other time points 
approached statistical significance. Self-reported adherence at baseline was significantly 
correlated with VL at 6 months when controlling for VL at baseline (rs=-0.310, p<0.01).   
The mean number of services utilized (out of possible 52) by all participants at 
baseline was 17.62 (SD=10.11) which decreased at T2 to 11.89 (SD=8.53), increased at 
T3 to 16.08 (SD=9.76), and decreased again at T4 to 14.38 (SD=8.60). A significant 
change in utilization was observed over time regardless of treatment condition [F (3, 
645)=19.07, p<0.001; partial η2 =0.073]. No time x condition interaction or between-
group difference in utilization were observed (Table 3.4).  
Upon entry into the study, 103 (55.1%) participants reported their VL to be 
undetectable with no significant difference in VL between treatment conditions. Change 
in percentages of those reporting an undetectable VL between baseline (T1) and T2, T3 
or T4 was not significant: 56.8% at T2, 66.0% at T3, and 66.1% at T4. As shown in Table 
3.3, at the 6-month follow-up, participants assigned to the HHRP-A group were more 
likely (74.6%; RR=1.49; 95% CI: 1.05, 2.13) to report an undetectable VL than those 
assigned to the HPC condition (56.7%, p<0.01).  
Processes 
Participants at baseline, regardless of group assignment, reported a mean support 
score of 67.98 (SD=17.61) out of a possible score of 95. A significant change in scores 
over time for both HPC and HHRP-A groups was observed, with mean scores increasing 
at T2 to 70.36 (+14.98), at T3 to 70.90 (+15.25) and at T4 to 70.46 (+14.04) [F=4.19, 
p<0.01, partial η2 =0.02]. The interaction between time point and condition approached 
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significance [F=2.37, p<0.06, partial η2 =0.01] whereby the experimental condition 
performed significantly better over time than the comparison group. No between-groups 
effect was observed when time points were collapsed.  
Stress measures were collected at baseline, T3 and T4. Participants regardless of 
condition assignment had a mean stress score of 26.87(SD=17.10) at baseline. The scores 
decreased to 25.99 (SD=15.55) at T3 and increased to 26.37 (SD=14.45) at T4. 
Differences in overall scores over time were not significant. No time x condition or 
between-groups effects were observed (Table 3.4).  
One significant correlation was identified between process and outcome variables: 
at 6 month follow-up for participants in the HHRP-A condition, adherence was positively 
associated with support (r=0.28, p<0.05; Table 3.5).  
	  
Table 3.2 (2). Outcome and process values (N/% and Mean/SD) at all available time points 
(N=243) 
  T1 T2 T3 T4 
  Mean (SD) 
N (%) 
Mean (SD) 
N (%) 
Mean (SD) 
N (%) 
Mean (SD) 
N (%) 
Adherence HPC 64/79 (81.0%) - 67/74 (90.5%) 50/62 (80.6%) 
>95% HHRP-A 63/74(85.1%) - 58/66 (87.9%) 53/57 (93%) 
 All 127/153 (83.0%) - 125/140 (89.3%) 103/119 (86.6%) 
Utilization HPC 17.62 (10.11) 12.55 (8.88) 15.79 (9.61) 14.74 (9.48) 
 HHRP-A 16.20 (9.58) 11.28 (8.19) 16.35 (9.93) 14.05 (7.74) 
 All 16.88 (9.85) 11.89 (8.53) 16.08 (9.76) 14.38 (8.60) 
Undetectable 
VL  
HPC 51/91 (56.0%) 50/82 (61.0%) 44/71 (62.0%) 34/60 (56.7%) 
HHRP-A 52/96 (54.2%) 42/80 (52.5%) 55/79 (69.6%) 50/67 (74.6%) 
All 103/187 (55.1%) 92/162 (56.8%) 99/150 (66.0%) 84/127 (66.1%) 
Stress HPC 27.36 (17.86) - 26.61 (16.54) 25.99 (15.55) 
HHRP-A 26.41 (16.44) - 28.31 (16.19) 26.72 (13.42) 
All 26.87 (17.10) - 27.49 (16.34) 26.37 (14.45) 
Support HPC 68.89 (17.80) 71.37 (13.90) 70.40 (15.77) 69.20 (14.52) 
 HHRP-A 67.14 (17.47) 69.44 (15.90) 71.37(14.81) 71.61(13.53) 
 All 67.98 (17.61) 70.36 (14.98) 70.90 (15.25) 70.46 (14.04) 
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Table 3.3 (3). Rate ratios for 95% ART adherence and undetectable viral load, by study 
assignment (N=243) 
 T1 
x 
 Condition 
 
T1-T2 
T2  
x  
Condition 
 
T1-T3 
T3 
x 
Condition 
 
T1-T4 
T4  
x 
Condition 
Self- 
Reported 
Adherence 
1.15 - - 1.69 0.87 0.97 1.55* 
Self-
Reported  
Undetectable 
VL 
0.96 5.52 0.84 6.08 1.19 2.49 1.49** 
* p=0.049 
** p=0.033 
 
 
 
 
Table 3.4 (4). Effects (F statistics) for continuous variables by time and study assignment 
(N=243) 
 Time (p) Time x Condition (p) Between Groups (p) 
Utilization 
(df: 3, 645) 19.07 (p<.001) 0.37 (p=0.75) 0.30 (p=0.58) 
Stress 
(df: 2, 440) 0.46 (p=0.61) 0.98 (p=0.37) 0.45 (p=0.50) 
Support 
(df: 3, 687) 4.19 (p=0.01) 2.36 (p=0.06) 0.01 (p=0.92) 
 *Derived from Greenhouse-Geisser statistics  
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Table 3.5 (5). Pearson and Spearman Rank correlations between outcome and process 
variables at baseline, post-intervention, 3 months, and 6 months (N=243) 
  Stress Support 
  HPC HHRP-A HPC HHRP-A 
Self-
Reported 
Adherence 
T1 -.07 .09 -0.22 0.06 
T3 .06 .19 -0.05 -0.05 
T4 .19 -.09 0.09 0.28* 
Service 
Utilization 
T1 0.04 0.05 0.06 0.00 
T2 - - 0.16 0.16 
T3 0.03 0.04 0.10 -0.14 
T4 0.02 -0.13 0.08 0.07 
Self-
Reported 
VL 
T1 0.002 0.10 0.04 0.14 
T2 - - 0.20 0.13 
T3 0.11 0.11 0.15 -0.05 
T4 0.06 0.00 -0.08 -0.11 
*significant at p<0.05 
 
 
DISCUSSION 
Participants enrolled in this study were at high risk of disease progression and 
reported risk behaviors associated with HIV transmission (Malow et al., 2012). Many 
reported less-than-optimal ART adherence, and most reported a detectable viral load and 
clinically significant NCI. The study group showed significantly lower NC functioning 
when compared to published norms. This study found that the HHRP-A group showed 
improved VL and adherence at 6 months post intervention. In addition, social support 
improved throughout follow up and was significantly associated with adherence at 6 
months post intervention.  
The evidence-based intervention evaluated in this study improved self-reported 
ART adherence in HIV-positive adults who used alcohol, more than the HPC at the six-
month follow-up time point, but not at other time points post-intervention. Other IMB 
model-based interventions, particularly those that employ strategies to facilitate learning 
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and retention, have yielded similar outcomes. Margolin et al. (2003) found success in 
improving self-reported adherence rates among methadone-maintained injection drug 
users after delivery of an adapted HHRP intervention. Another study developed an IMB-
based health literacy training which showed some effectiveness in improving adherence 
among a heterogeneous sample of HIV-positive adults (Ownby, Waldrop-Valverde, 
Caballero, & Jacobs, 2013). Similar to the research presented here, both of those 
intervention studies involved PLWH who were engaged in clinical care, adherence rates 
were high at the outset and “adequate adherence” was set at 95%. Ownby found the 
greatest improvement among participants who began at the lowest levels of adherence; 
however that study did not include a comparison condition. Additionally, neither of the 
previous interventions studies examined prospective outcomes. Finally, although the 
accuracy and veracity of self-report adherence measures vary greatly in the literature 
(Simoni, Kurth, et al., 2006), the fact  that adherence values at baseline in this study were 
significantly correlated with VL at 6 months suggest high accuracy in adherence 
reporting. 
While improvement in ART adherence is a promising outcome, undetectable VL 
should be the ultimate marker of health improvement. Uncontrolled viral replication and 
associated immune activity can result in a chronic inflammatory state, organ damage and 
other conditions, including  NC impairment (Thompson et al., 2012). In this study, 
significantly more participants in the HHRP-A condition reported an undetectable VL six 
months, but not at other time points after the intervention. A recent meta analysis 
examining associations between both self-reported and directly observed ART adherence 
and VL suggested that longer term analysis, such as the 6-month time frame used in this 
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study, yields stronger associations (Kahana, Rohan, Allison, Frazier, & Drotar, 2013). 
Also, an incrementally larger proportion of the sample in the experimental condition 
reported an undetectable VL at each follow-up time point, but this improvement was not 
statistically significant. The magnitude of association between these variables is often due 
to methodological factors, particularly using a dichotomous measure of VL (Kahana et 
al., 2013). Hence, a continuous measure of VL could have provided different outcomes in 
this study. 
Although this study did not employ a mediated model, an attempt was made, 
nonetheless, to explore possible mechanisms through which improvements in outcomes 
may have operated. Effectiveness of the intervention in improving social support and 
reducing stress were mixed. The intervention included numerous stress-reduction and 
relaxation activities; however perceptions of life stress appeared to be unaffected by the 
intervention, in contrast to  trials delivering similar cognitive-behavioral techniques, 
which have resulted in better stress outcomes (Antoni et al., 1991; Lopez et al., 2011). 
Social support, on the other hand, improved significantly as a function of both time and 
treatment condition. Between baseline and post-intervention, participants’ participation in 
either group may have provided a greater perception of support (Lutgendorf et al., 1998). 
However, support scores for the HPC condition declined after T2, while participants in 
the HHRP-A group continued to report increased social support throughout the study 
period. This longitudinal difference in social support between the two conditions could 
have been due to the difference in format of the two intervention groups; HHRP-A met 
over a longer period of time. 
146 
	  
The study did not completely support the buffering model of social support. 
Although at 6-month follow-up, report of >95% adherence among participants 
randomized to the HHRP-A condition was positively correlated with social support, 
adherence was not correlated with stress at this time point. The relationship between 
social support, stress and adherence has been repeatedly supported in the literature (Catz 
et al., 2000; Gonzalez et al., 2004; Paterson et al., 2000; Singh et al., 1999), however the 
use of more focused indicators of support, particularly instrumental or adherence-specific 
support scales, could yield stronger associations with health behavior outcomes 
(DiMatteo, 2004; Lehavot et al., 2011; Simoni, Frick, et al., 2006). 
Contrary to one of this study’s hypotheses, a significant reduction in reported 
service utilization was observed for all participants in the months following the 
intervention. This finding may be explained by changes in residential status during this 
study: nearly a quarter of the sample was in residential drug or alcohol treatment at 
baseline, dropping to under 5% in residential treatment at follow up time points. As 
reported in prior studies, a change in structured inpatient support is likely to have 
disrupted participants’ access to services (Arno et al., 1996; Kim, Kertesz, Horton, 
Tibbetts, & Samet, 2006; Smith et al., 2000). Additionally, a comprehensive literature 
review by Azar (2010) suggests that service utilization may be less consistent among 
persons abusing alcohol than those abusing other drugs. The supportive inpatient status of 
many participants at baseline may also help explain the higher-than-expected adherence 
rates in this sample (Azar et al., 2010; Sylla, Bruce, Kamarulzaman, & Altice, 2007). 
Eighty-three percent of participants in this study reported adequate adherence at baseline, 
whereas in the intervention evaluation study by Margolin et al. (2003) baseline self-report 
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measures of adherence were collected prior to entering a structured substance abuse 
treatment program and only 51% reported adequate adherence.  
Several strengths of this study are important to note. While all participants were 
HIV-seropositive and had a history of alcohol abuse, the sample was still heterogeneous, 
representing a diverse cross-section of hard-to-access, high-risk adults living in urban 
Miami-Dade County. In addition, the intervention was highly comprehensive, offering 
multiple topics relevant to HIV-positive alcohol abusers using cognitive remediation 
strategies to improve efficacy for those with NCI. Both arms of the study were manual-
guided, ensuring treatment fidelity. Finally, process variables were integrated into this 
study and the intervention design (National Institute of Mental Health Multisite HIV 
Prevention Trial Group, 2001). 
Unique features and limitations of this study should also be considered when 
interpreting results. For ethical reasons, to ensure that participants in both arms received 
equitable treatment benefit, the study required that the comparison condition offered a 
healthy alternative to HHRP-A. A dose-effect analysis between groups could not be 
conducted nor was it possible to determine which treatment components were most 
effective. Similarly, participants in the HPC arm attended a significantly greater number 
of sessions than the HHRP-A group. Although the two programs were designed to be 
equivalent on both time and administration, the HPC group was condensed into two days 
where the HHRP-A group was conducted over the course of several weeks, likely 
contributing to greater absenteeism. Also, interpretation of findings may be limited by the 
loss of over 30% of the sample by the 6-month follow-up time point. Finally, all 
measures in this study were self-report. While both VL and adherence self-report 
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measures were checked for veracity by correlating measures with serum VL at baseline in 
this study, it should nonetheless be noted that self-reported treatment adherence, in 
particular, has been found to be inflated in some samples (Duran et al., 2001) and 
adequately correlated with observational adherence measures in other studies (Shi et al., 
2010).  
In conclusion, the results of this study suggest that treatment adherence and viral 
load could be improved greatly by incorporating comprehensive, cognitive-behavioral 
risk reduction interventions into HIV and substance abuse care. It is equally important 
that interventions employ essential cognitive remediation strategies to further enhance 
skills development and information retention among persons with HIV-related NC 
impairment. The implementation and further translation of evidence-based interventions 
require considerable time, effort and funding. Thus, the goal after finding an intervention 
effective in community settings is to synthesize results for rapid dissemination to 
clinicians and care providers in order to reduce the risk of HIV transmission and disease 
progression on a public level (Copenhaver et al., 2012; Lyles, Crepaz, Herbst, & Kay, 
2006).  
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CHAPTER VI 
SUMMARY OF CONCLUSIONS 
The overarching purpose of the three studies comprising this dissertation was to 
investigate the extent to which biopsychosocial factors—including NC impairment —
influence ART adherence, service utilization and VL before and after the delivery of an 
evidence-based intervention among HIV-positive alcohol abusers. Each study built upon 
information gained in the preceding study, concluding with the final analysis which 
evaluated the effectiveness of the HHRP-A intervention. The HHRP-A intervention is 
unique in two ways: first, it is delivered using a holistic, harm-reduction approach, 
addressing multiple, complex psychosocial factors prevalent in the lives of people who 
abuse drugs or alcohol; second, the intervention includes cognitive remediation strategies 
to maximize information retention and synthesis for PLWH who may also suffer from a 
degree of neurocognitive impairment. 
The first study examined factors hypothesized to contribute to NCI: drug and 
alcohol use and time living with HIV. This baseline analysis, using structural equation 
modeling, positioned five exogenous variables—years living with HIV; time from HIV 
diagnosis to seeking care; and days using alcohol, marijuana and cocaine in the prior 
three months—as predictors of three NC measures selected to address a range of 
cognitive domains. Mean scores on NC measures for this sample were significantly lower 
than mean normative scores suggesting a degree of impairment. In addition, both 
marijuana use and years living with HIV were associated with poorer scores on the CTT2 
which measures several executive functions including information processing. 
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The second study also used structural equation modeling at baseline to test a 
biopsychosocial model predicting VL with ART adherence as a mediator. Independent 
variables included tangible social support, barriers to ART adherence, and stress. 
Moderators included alcohol use, marijuana use and NC impairment. Employing Baron 
and Kenny’s 4-step approach to testing mediation (Baron & Kenny, 1986; James & Brett, 
1984; Judd & Kenny, 1981), the relationship between barriers to adherence and VL was 
found to be to a considerable degree mediated by ART adherence.   
The final study was a randomized controlled trial, modeled after the research 
conducted by Margolin et al. (2003) who conducted a previous assessment of the HHRP 
intervention adapted for PLWH who were intravenous drug users enrolled in a 
methadone maintenance program. Participants were randomized to the HHRP-A or a 
comparison group and data were collected at baseline, post-intervention, 3-month, and 6-
month follow-up time points. Participants in the HHRP-A condition were significantly 
more likely to report optimal ART adherence and undetectable VL at 6 months post-
intervention. A significant time-by-condition effect was also observed in social support, 
with the experimental condition showing greater improvement than the comparison 
group. 
Some limitations and strengths of this research are important to note. These 
participants were drawn from clinical sites and may not be representative of PLWH who 
are not engaged in care for HIV. Reporting bias should be considered in interpreting 
outcomes; this proportion of participants who were engaged in care may also account for 
the relatively high adherence rates reported in this sample. Nearly a quarter of the sample 
was in residential addictions treatment at baseline and it is possible that recent substance 
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use was underreported or atypically low for the group. Measurement issues should be 
considered when interpreting this study’s results. A battery of only three NC assessment 
instruments were used which may limit the sensitivity for finding NC impairment. Also, 
ART adherence was a self-reported measure which could provide an underestimate of 
actual adherence rates. This research also had several strengths. The sample was highly 
heterogeneous, contributing to the external validity of the outcomes. In addition, the 
HHRP-A intervention assessed in Aim 3 was manual-guided contributing to the internal 
validity of outcomes.  
Overall findings from the three studies suggest that: (a) marijuana and time living 
with HIV may be important contributors to NC impairment among PLWH; (b) a 
biopsychosocial model can be an effective tool for understanding factors that contribute 
to changes in ART adherence and VL; and (c) providing comprehensive health promotion 
interventions such as HHRP-A particularly those incorporating cognitive remediation 
strategies, could improve health outcomes for HIV-seropositive substance users.  Future 
research should further investigate possible substance use and HIV-related factors (as 
well as interactions between these variables) contributing to NC impairment.  Greater 
understanding of psychosocial variables and their direct effect upon viral suppression and 
disease progression among PLWH is also needed. Finally, health outcomes for PLWH 
could be improved by the ongoing delivery, evaluation and adaptation of holistic, 
evidence-based interventions that address the complex medical, psychological, cognitive, 
and social needs of PLWH who use alcohol and other drugs. 
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APPENDIX 2: recruitment sites accessed by parent study 
 
1. Borinquen Health Care Center* 
2. Florida Department of Health: Broward County Department Sexually Transmitted 
Disease Program 
3. Center for Haitian Studies 
4. South Florida Provider Coalition 
5. The Salvation Army 
6. Care Resource 
7. Empower U, Inc.* 
8. The Village* 
9. South Florida AIDS Network 
10. The Center for Positive Connections Support & Resource Center 
11. South Beach AIDS Project, Inc. 
12. Miami Beach Community Health Center, Inc. 
13. Helen B. Bentley Family Health Center, Inc. 
 
*Indicates sites from where the majority of participants were recruited.  
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APPENDIX 3: additional Tables and Figures for Manuscript 1 
 
Figure Appendix 3.1. Hypothesized directional model with one proposed latent 
variable 
 
 
 
Table Appendix 3.1. Correlation matrix for all variables in the model (N=370) 
 AVLT CTT2 SCT Alcohol Marijuana Cocaine Yrs HIV1 Dx to 
Tx2 
AVLT1  1.000        
CTT22 -0.293 1.000       
SCT3 -0.206 0.174 1.000      
Alcohol  -0.040 0.002 0.070 1.000     
Marijuana 0.061 0.070 -0.016 0.171 1.000    
Cocaine 0.003 -0.038 0.051 0.386 0.195 1.000   
Yrs HIV4  -0.087 0.176 0.095 0.081 -0.056 0.046 1.000  
Dx to Tx5 0.030 0.002 -0.038 0.021 0.139 0.012 0.246 1.000 
1AVLT Auditory Verbal Learning Test 
2CTT2 Color Trails Test 2 
3SCT Short Category Test 
4Yrs. HIV Duration of known HIV infection in years 
5Dx. to Tx Years between diagnosis of HIV infection and initiation of ART 
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APPENDIX 4: ADDITIONAL FIGURE FOR MANUSCRIPT 2 
 
Figure Appendix 4.1. Hypothesized partially mediated model predicting viral load, 
moderated by cognitive and behavioral factors (N=246) 
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APPENDIX 5: ADDITIONAL FIGURES FOR MANUSCRIPT 3 
Figure Appendix 5.1. Mean number of services utilized at each time point (N=243) 
Figure Appendix 5.2. Mean support scores, all time points (N=243) 
Time Point 
Time Point 
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Figure Appendix 5.3. Mean stress scores at T1, T3 and T4 (N=243) 
Figure Appendix 5.4. Percent participants reporting >95% adherence to ART at 
each time point. N=243 
Time Point 
Time Point 
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Figure Appendix 5.5. Proportion of participants reporting undetectable VL at each 
time point (N=243) 
Time Point 
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